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ABSTRACT 
During the past decade Chinese people have gradually changed their lifestyles following the rapid 
development of the economy. Lifestyle changes in the population have increased the prevalence of 
type 2 diabetes and obesity, especially in urban areas. However, no study has been conducted on 
relationship between the metabolic syndrome and incident diabetes in China.   
This study was designed to evaluate the ability of the five definitions, major components and 
changes in features of the metabolic syndrome with respect to the prediction of type 2 diabetes in a 
Chinese population.  
The Beijing Project of National Diabetes Survey was carried out in 1994, and a follow-up study of 
627 high-risk non-diabetic individuals at baseline was untaken in 1999. A total of 146 subjects 
developed diabetes during the 5-year follow-up.  
The definitions of the metabolic syndrome defined by the National Cholesterol Education Program 
(NCEP) Expert Panel and the European Group for the Study of Insulin Resistance (EGIR) were 
somewhat insensitive for predicting incident diabetes (especially in men), only detecting about 27% 
of Chinese men with incident diabetes. Both impaired fasting glucose and impaired glucose 
tolerance combined were associated with a 9-fold increased risk of incident diabetes in both men 
and women. Isolated impaired glucose tolerance was also associated with a 7.8-fold increased risk 
of future diabetes in Chinese men. Factor analysis revealed four factors, rather than only one factor, 
in non-diabetic and diabetic subjects. Blood pressure was not linked to insulin resistance. The 
urinary albumin excretion rate was associated with the glucose factor in diabetic subjects. The 
obesity and glucose factors strongly predicted the development of diabetes. An increase in the 
prevalence of obesity was associated with a 2.2-fold increased risk of the development of impaired 
glucose regulation or incident diabetes after adjustment for the confounding factors.  
The results suggest that further studies on the definition of the metabolic syndrome should focus on 
the potential ethnic differences in obesity and insulin resistance. In Chinese men, isolated impaired 
glucose tolerance is a better predictor of incident diabetes than impaired fasting glucose. Different 
physiological processes associated with various components of the metabolic syndrome contain 
unique information about diabetes risk. Microalbuminuria is more likely to be a complication of 
diabetes or hypertension than a marker of the metabolic syndrome. Obesity may be a more 
important risk factor for the development of impaired glucose regulation or diabetes than other 
features of the metabolic syndrome.   
Keywords: metabolic syndrome, definition, type 2 diabetes, insulin resistance, incidence 
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8ABBREVIATIONS 
AACE        American Association of Clinical Endocrinologists  
APC  Asia-Pacific criteria  
BP  blood pressure 
BMI  body mass index 
CNHS  China's Nutrition and Health Survey  
CVD  cardiovascular disease  
DBP  diastolic blood pressure 
DPP           Diabetes Prevention Program  
DPS           Finnish Diabetes Prevention Study 
EGIR        European Group for the Study of Insulin Resistance 
Fin            fasting insulin 
FPG          fasting plasma glucose 
HDL         high-density lipoprotein 
HOMA-IR homeostasis model assessment of insulin resistance 
IDF                International Diabetes Federation 
IFG                impaired fasting glucose  
I2/G2                     2-h insulin/2-h glucose 
IGR                impaired glucose regulation 
IGT impaired glucose tolerance 
InterASIA International Collaborative Study of Cardiovascular Disease in Asia 
IRAS              Insulin Resistance Atherosclerosis Study  
ISI                   insulin sensitivity index  
LDL                low-density lipoprotein 
MetS the metabolic syndrome 
MONICA       Monitoring of Trends and Determinants in Cardiovascular Disease 
NEFAs non-esterified fatty acids  
NCEP              National Cholesterol Education Program 
NFG                 normal fasting glucose 
NGT                 normal glucose tolerance 
OGTT               oral glucose tolerance test 
OR                    odds ratio    
PPAR?              peroxisome proliferator-activated receptor gamma  
2-h PG              2-h post glucose load  
QTL                  quantitative trait loci 
QUICKI            quantitative insulin sensitivity check index  
RR                     relative risk  
SAHS San Antonio Heart Study  
SAT                  subcutaneous abdominal tissue 
SBP                   systolic blood pressure 
TC                      total cholesterol 
TG                      triglycerides 
VLDL               very-low-density lipoprotein  
WC                     waist circumference 
WHO                  World Health Organization 
WHR                  waist-to-hip ratio 
UAER                 urinary albumin excretion rate  
VAT                    visceral abdominal tissue 
VLDL                very-low-density lipoprotei
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1. INTRODUCTION 
The clustering of hypertension, dyslipidaemia, glucose intolerance, insulin resistance, 
hyperinsulinemia, microalbuminuria, and obesity (particularly central obesity) was termed the 
metabolic syndrome (MetS). An important feature of the syndrome is insulin resistance, 
characterized by increased serum fasting insulin levels among non-diabetic individuals in 
epidemiological studies. Thus, it has been called syndrome X or insulin resistance syndrome. 
Despite the fact that the underlying mechanism of the syndrome is not completely understood, 
obesity and sedentary lifestyle coupled with an unbalanced diet and still largely unknown genetic 
factors, interact to produce the syndrome. It has been proposed that this syndrome is a powerful 
determinant of type 2 diabetes and cardiovascular disease (CVD).  
To aid in the clinical application and research of the syndrome, the World Health Organization 
(WHO) consultation for the classification of diabetes and its complications published the first 
definition of the syndrome and named it MetS. Subsequently, the European Group for the Study of 
Insulin Resistance (EGIR), the National Cholesterol Education Program (NCEP) Expert Panel, the 
American Association of Clinical Endocrinologists (AACE), and the International Diabetes 
Federation (IDF) also proposed different definitions. However, almost all the cut-off points for 
abdominal obesity used in the definitions of the WHO, the NCEP and the EGIR were based on the 
results obtained in a Caucasian populatio. It has been unknown whether or not the definitions are 
suitable for a Chinese population. Although three studies have assessed the association of MetS 
defined by the NCEP and the WHO criteria with the development of diabetes in Finns, Pima 
Indians, Mexican Americans, and non-Hispanic whites, none of them addresses the association of 
MetS based on the other definitions with the risk of type 2 diabetes both in men and women.  
It is now commonly agreed that no more controlled trials are needed to prove that type 2 diabetes 
can be prevented, and it is now more important to find high-risk non-diabetic individuals and to 
assess their relations to the risk of diabetes and death. Evidence from many prospective studies has 
indicated that subjects with impaired glucose tolerance (IGT) have markedly higher risk for the 
development of type 2 diabetes and for all-cause and cardiovascular mortality than subjects with 
normal glucose. A few studies have assessed the risk of progression to diabetes in subjects with 
impaired fasting glucose (IFG) and normal fasting glucose (NFG) in white, Pima Indian, and other 
populations. The development of type 2 diabetes in high-risk non-diabetic individuals is less known 
in China.  
Factor analysis, a statistical technique for studies including interrelating variables, has been applied 
to investigate the risk factor clustering in MetS and to predict coronary heart disease or total and 
CVD mortality. However, little information is presently available on the mechanism with which the 
major components of MetS including urinary albumin excretion rate (UAER) relate to each other in 
non-diabetic and diabetic individuals. Furthermore, few prospective studies evaluate the extent to 
which MetS or its individual components predict the development of type 2 diabetes using factor 
analysis.  
The current understanding of the pathogenesis of type 2 diabetes is mainly based on a large number 
of cross-sectional and prospective studies. In these studies non-diabetic individuals are followed for 
several years in order to determine incident cases of diabetes without repeating assessment of other 
metabolic characteristics, except for an assay of plasma glucose during follow-up. In fact, only the 
studies in the Pima Indian population have examined the changes in anthropometric characteristics, 
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insulin secretion, and insulin action during the progression from normal glucose tolerance (NGT) to 
IGT, to diabetes. Thus far, no study has directly addressed the effects of changes in the components 
of MetS on the transition to diabetes in other populations.  
In this study, a screening survey for type 2 diabetes was conducted in 1994 and a follow-up study 
for high-risk non-diabetic individuals was carried out in 1999. The study first evaluated the ability 
of the WHO, the EGIR, the NCEP, the AACE and the IDF definitions for MetS in relation to the 
prediction of type 2 diabetes both in men and women. Second, it compared the relative risk of the 
development of diabetes between normal glucose homeostasis and isolated IFG, isolated IGT, and 
both IFG and IGT. Third, it applied factor analysis to investigate how the major components of 
MetS related to each other and to the development of diabetes in the Chinese population. Finally it 
investigated the changes in the features of MetS during the transition from one state of glucose 
homeostasis to another, and understood the relative contributions of these changes to the 
development of impaired glucose regulation (IGR) or type 2 diabetes. 
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2. LITERATURE REVIEW     
2.1 What is MetS? 
In 1923 Kylin first described the clustering of hypertension, hyperglycemia, and gout as a syndrome1.
In 1988 Reaven reintroduced the concept of syndrome X for the clustering of cardiovascular risk 
factors, including resistance to insulin-stimulated glucose uptake, glucose intolerance, 
hyperinsulinemia, increased very-low-density lipoprotein (VLDL) triglycerides, decreased high-density 
lipoprotein (HDL) cholesterol, and hypertension2. Subsequently, several other components to the 
syndrome, such as obesity and especially its central distribution, microalbuminuria, hyperuricaemia, 
and abnormalities in haemostatic factors have been added 3-7. However, controversies still exist as to 
whether or not microalbuminuria is a component of the syndrome8-10. In addition, the syndrome has 
been given several different names like the deadly quartet, the insulin resistance syndrome, the 
metabolic cardiovascular syndrome, the insulin resistance-dyslipidaemia syndrome, and plurimetabolic 
syndrome 11-15. The name “insulin resistance syndrome” has been widely used and refers to insulin 
resistance as a common denominator of the syndrome16. In 1999, the WHO proposed a unifying 
definition for the syndrome and chose to call it MetS rather than the insulin resistance syndrome17. The 
reason was mainly that it was not considered established that insulin resistance was the cause of all the 
components of the syndrome.  
2.2 Five definitions of MetS 
Despite abundant research on the subject of MetS, the criteria used for diagnosing MetS are different 
across studies, causing confusion when assessing prevalence rates across countries. To aid in the 
clinical practice and research of the syndrome, the WHO, the EGIR, the NCEP, the AACE and the IDF 
have proposed different definitions17-22. The new IDF definition emphasizes the importance of central 
obesity defined by ethnic specific values (Table 2.2).  
Table 2.2. WHO, EGIR, NCEP, AACE and IDF definitions of MetS 
WHO definition 
Diabetes (fasting plasma glucose ≥7.0 mmol/l and/or 2-hour plasma glucose ≥11.1 mmol/l), or impaired glucose 
regulation (fasting plasma glucose 6.1-6.9 mmol/l and/or 2-hour plasma glucose 7.8-11.0 mmol/l), and/or insulin 
resistance (below lowest quartile of glucose uptake in the euglycaemic clamp), and two or more of the following:  
? Raised triglycerides (≥1.7 mmol/l) and/or low HDL-cholesterol (<0.9 mmol/l in men, < 1.0 mmol/l in women)
? Central obesity (waist-to-hip ratio >0.90 in men, >0.85 in women) and/or body mass index (BMI) >30 kg/m2
? Raised blood pressure (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) 
? Microalbuminuria (urinary albumin excretion rate ≥20 μg/min or albumin/creatinine ratio ≥30 mg/g)
EGIR definition for non-diabetic individuals 
Hyperinsulinaemia (fasting insulin concentrations in the highest quartile) and at least two of the following: 
? Hyperglycaemia (fasting plasma glucose ≥6.1 mmol/l) 
? Central obesity (waist circumference ≥94 cm in men, ≥80 cm in women) 
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? Hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or treated for 
hypertension)  
? Dyslipidaemia (triglycerides >2.0 mmol/l or low HDL-cholesterol < 1.0 mmol/l or treated for dyslipidaemia) 
NCEP definition 
Three or more of the following: 
? Abdominal obesity (waist circumference >102 cm in men, >88 cm in women)  
? Triglycerides ≥1.7 mmol/l  
? HDL-cholesterol < 1.03 mmol/l in men, <1.29 mmol/l in women  
? Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg   
? Fasting plasma glucose ≥6.1mmol/l 
AACE definition for non-diabetic individuals 
Two or more of the following:
? Triglycerides ≥1.7 mmol/l 
? HDL-cholesterol < 1.03 mmol/l in men, <1.29 mmol/l in women 
? Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg or current use of 
antihypertensive medications 
? 2-hour plasma glucose 7.8-11.0 mmol/l or fasting plasma glucose 6.1-6.9 mmol/l (IFG) (IFG was added in 
updated AACE criteria) 
IDF definition  
Central obesity defined as ethnicity specific values of waist circumference (≥ 90cm for Chinese men and ≥80cm for 
Chinese women) and at least two of the following: 
? Raised triglycerides levels (≥1.7 mmol/l), or specific treatment for this lipid abnormality  
? Reduced HDL-cholesterol (< 1.03 mmol/l in men, <1.29 mmol/l in women), or specific treatment for this lipid 
abnormality 
? Raised blood pressure (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg), or 
treatment of previously diagnosed hypertension 
? Raised fasting plasma glucose (≥5.6 mmol/l), or previously diagnosed type 2 diabetes. 
        If above 5.6 mmol/l, OGTT is strongly recommended but is not necessary to define presence of the syndrome 
2.3 Prevalence of MetS in some countries  
Applying the NCEP definition of MetS in a representative U.S. sample of 8,814 men and women 
aged 20 years and older from the Third National Health and Nutrition Examination Survey (1988-
1994), the unadjusted and age-adjusted prevalence of MetS was 21.8% and 23.7%, respectively. 
The prevalence increased from 6.7% among participants aged 20 through 29 years to 43.5% and 
42.0% for participants aged 60 through 69 years and aged at least 70 years, respectively. Mexican 
Americans had the highest age-adjusted prevalence of MetS (31.9%). The age-adjusted prevalence 
was similar for men (24.0%) and women (23.4%). However, African American women had a 57% 
higher prevalence than African American men did, and Mexican American women had a 26% 
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higher prevalence than Mexican American men did. Using 2000 census data, about 47 million U.S. 
residents have MetS23. The data from eight European studies, which included 8,200 men and 9,363 
women, showed that in non-diabetic subjects the frequency of the WHO-defined syndrome varied 
between 7% and 36% for men aged 40 to 55 years, and for women of the same age, between 5% 
and 22%; the EGIR-defined syndrome was less frequent than the WHO-defined syndrome (1% to 
22% in men, 1% to 14% in women 40-55 years)24. In another study based on 11 prospective 
European cohort studies comprising 6,156 men and 5,356 women without diabetes and aged from 
30 to 89 years, the age-standardized prevalence of MetS defined by the modified WHO definition 
was slightly higher in men (15.7%) than in women (14.2%). The overall prevalence of the WHO-
defined MetS in non-diabetic adult Europeans is 15%25. In Omani adults aged 20 years and over, 
living in the city of Nizwa, the age-adjusted prevalence of the NCEP-defined MetS was 21.0% 
(men: 19.5%, women: 23.0%) 26. Among 40,698 Korean metropolitan subjects (26,528 men, 14,170 
women) aged 20-82 years, the age-adjusted prevalence of the NCEP-defined MetS was 6.8% in 
total (5.2% male, 9.0% female). Using the Asia-Pacific criteria (APC) for abdominal obesity based 
on waist circumference (WC) (APC-WC: ≥ 90 cm in men, ≥ 80 cm in women), the prevalence rates 
of MetS increased to 10.9% (9.8% male, 12.4% female). The subjects over 70 years of age had a 
14-fold increased risk for MetS than those aged 20-29 years, and females had higher prevalence 
rates than males in age groups older than 50 years27. The 1998 Singapore National Health Survey 
involving 4,723 men and women of Chinese, Malay, and Asian-Indian ethnicity aged 18-69 years, 
demonstrated that the age-adjusted prevalence rates of the NCEP-defined MetS were 9.4, 18.7, and 
20.4% for Chinese, Malays, and Asian-Indians, respectively. Using the APC criteria, the analogous 
prevalence rates increased to 14.8, 24.2, and 28.8% for the three ethnic groups, respectively28.
2.4 Prevalence of MetS or individual components of MetS in China 
According to the fourth China's Nutrition and Health Survey (4th CNHS), which was carried out 
between August and December 2002 among population-based samples of 272,023 individuals from 
31 provinces, the prevalence of obesity (BMI ?30) in Chinese adults aged 18 years and older was 
7.1%, while in some large cities 12.3% of adults and 8.1% of children were classified as obese and 
30% of adults were overweight (BMI ?25). About 19% of Chinese adults had hypertension or 
dyslipidaemia29. The International Collaborative Study of Cardiovascular Disease in Asia 
(InterASIA) was conducted in China and Thailand between 2000 and 2001, including a nationally 
representative sample of 15,540 individuals from ten provinces of China. The study displayed that 
19.4% of Chinese adults aged 35-74 years had hypertension, 24.8% had raised triglycerides levels 
and 33.9% had low HDL cholesterol. The age-standardized prevalence of the NCEP-defined MetS 
was 9.8% in men and 17.8% in women30-32 (Table 2.4). 
2.5 Epidemiology of type 2 diabetes 
2.5.1 Definition, classification, and diagnosis of diabetes  
The term diabetes mellitus describes a metabolic disorder of multiple aetiologies characterized by 
chronic hyperglycaemia with disturbances of carbohydrate, fat, and protein metabolism resulting 
from defects in insulin secretion and/or insulin action. The 1999 WHO criteria proposed four major 
classes of diabetes and named them, type 1, type 2, other specific types, and gestational diabetes. 
90% of people with diabetes have type 2 diabetes17. According to the 1999 WHO criteria, the 
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present study only discussed type 2 diabetes and classified the participants into five categories of 
glucose status based on fasting plasma glucose (FPG) and 2-h postload glucose (2-h PG) (Table 
2.5.1). In addition, the American Diabetes Association (ADA) has suggested that IFG should be 
redefined as an FPG of 5.6-6.9 mmol/l33.
Table 2.4 The prevalence of obesity, hypertension, and dyslipidaemia in China based on 4th CNHS and InterASIA 
    Prevalence (%) 
Study (year) Area n Age 
(years) 
25?BMI<30 BMI ?30 hypertension dyslipidaemia 
4th CNHS (2002) 31 provinces 272,023 ?18 22.8 7.1 18.8 18.6 
    Large cities  ?18 30.0 12.3   
   ?12  8.1   
InterASIA (2000) 10 provinces 15,540 35-74   19.4 24.8 (TG ? 1.7mmol/l) 
       33.9 (HDL< 1.0mmol/l  
in men; <1.3 mmol/l  
in women) 
  7,526 (M)  21.8*  5.0**   
  8,014 (F)  23.4 * 7.7**    
Hypertension: blood pressure ?140/90 mmHg or antihypertensive medication.
Dyslipidaemiais defined as at least one of the following: HDL< 0.91 mmol/l; total cholesterol ? 5.21 mmol/l; 
triglycerides ? 1.7 mmol/l. 
 M: male; F: female. 
 * 25?BMI<29. ** BMI ?29.
Table 2.5.1 The categories of glucose status based on the 1999 WHO criteria 
NFG and NGT Isolated IFG Isolated IGT Combined IFG and IGT Diabetes 
FPG mmol/l <6.1  6.1 - 6.9  <6.1  6.1 - 6.9  ?7.0 
 and and and and and/or 
2-h PG mmol/l <7.8 <7.8  7.8-11.0  7.8-11.0  ?11.1 
2.5.2 Prevalence of type 2 diabetes 
In 2003, it was estimated that approximately 194 million people worldwide, or 5.1% in the age 
group 20-79, have diabetes, and around two-third of these people lived in developing countries. 
This estimate is expected to increase to some 333 million, or 6.3% in the adult population, by 2025. 
The European Region with 48 million and Western Pacific Region with 43 million currently have 
the highest number of people with diabetes. However, the prevalence rate of 3.1% for the Western 
Pacific Region is significantly lower than 7.9% in the North American Region and 7.8% in the 
European Region. By 2025, the region with the greatest number of persons with diabetes is 
expected to change to the South-East Asian Region with about 82 million. The region’s prevalence 
of 7.5% will however continue to be lower than that of North America, estimated at 9.7%, and 
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Europe34. The 10 countries35 estimated to have the highest numbers of people with diabetes in 2000 
and 2030 are listed in table 2.5.2.  
Table 2.5.2 List of countries with the highest numbers of estimated cases of diabetes for 2000 and 2030 
 2003  2030  
Ranking Country People with diabetes 
(millions) 
Country People with diabetes 
(millions) 
1 India 31.7 India 79.4 
2 China 20.8 China 42.3 
3 U.S. 17.7 U.S. 30.3 
4 Indonesia 8.4 Indonesia 21.3 
5 Japan 6.8 Pakistan 13.9 
6 Pakistan 5.2 Brazil 11.3 
7 Russia 4.6 Bangladesh  11.1 
8 Brazil 4.6 Japan 8.9 
9 Italy 4.3 Philippines 7.8 
10 Bangladesh 3.2 Egypt 6.7 
2.5.3 Age, gender and urban/rural distributions  
According to the previous two references, the 40-59 age group currently has the greatest number of 
persons with diabetes. By 2025, because of the aging of the world’s population, there will be 146 
million aged 40-59 and 147 million aged 60 or older with diabetes. The estimates for both 2003 and 
2025 showed a female predominance in the number of persons with diabetes. The female numbers 
were about 10% higher than for male. In developing countries, the majority of people with diabetes 
are in the 45- to 64-year age range. In contrast, the majority of people with diabetes in developed 
countries are older than 64 years of age. In 2003, the number of people with diabetes in urban areas 
was 78 million, compared to 44 million persons with diabetes in rural areas in countries not 
considered to be established market economies or former socialist economies. By 2025 it is 
expected that this discrepancy will increase to 182 million urban and 61 million rural persons with 
diabetes.  
2.5.4 Prevalence of type 2 diabetes in China 
In 1980 the first National Diabetes Survey (1st NDS) investigated 300,000 people in 14 provinces 
and cities. The results showed that the prevalence of type 2 diabetes in the subjects aged 30 years or 
older was 0.9% in China36. In 1986 the Da Qing IGT and Diabetes Study investigated 10,660 men 
and women from 33 health care clinics in the city of Da Qing. The prevalence of type 2 diabetes 
was reported to be about 1% among subjects aged 25 to 64 years living in this urban community37.
In 1994 the second National Diabetes Survey (2nd NDS) from 19 provinces and areas found that 
the prevalence of type 2 diabetes in subjects aged 25 years or older increased to 3.1%38. In this 
survey, the prevalence in the Beijing area in subjects aged 25 years or older was higher than the 
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overall prevalence, reaching 3.4%39. The results from the InterASIA reported that China’s 
prevalence of type 2 diabetes in 2000 was six times that in 1980 and the prevalence among residents 
living in urban was higher than those living in rural areas40. Recently, 4th CNHS showed that the 
overall prevalence of type 2 diabetes in subjects aged 18 years and older was 2.6%, but the 
prevalence in residents aged 20 years and older in the big cities reached 6.4% (Table 2.5.4). 
Table 2.5.4 The prevalence of type 2 diabetes or IGT or IFG in China 
    Prevalence   
Study (year) Area n Age (years) Diabetes (%) IGT (%) IFG (%) 
1st NDS (1980) 14 provinces 107,954 ?30 0.9 0.8  
Da Qing (1986) Da Qing 109,629 25-64 1.0 0.7  
  110,660 >25 1.3 0.8  
2nd NDS (1994) 19 provinces 213,515 25-64 2.5 3.2  
  224,251 >25 3.1 4.0  
      Beijing 20,682 ?25 3.4 3.3  
 InterASIA (2000) 10 provinces 15,540 35-74 5.5  7.3  
       Urban 7,893 35-74 7.8  7.7  
        Rural 7,647 35-74 5.1  7.4  
4th CNHS (2002) 31 provinces 272,023 ?18 2.6  1.9  
      Big cities  ?20 6.4   
2.6 Incidence of type 2 diabetes 
An analysis of six prospective studies have reported cumulative incidences of type 2 diabetes 
ranging from 23% to 62% among persons with IGT during a 2- to 27- year follow-up41. The 
incidence was higher among Hispanic, Mexican-American, Pima, and Nauruan populations 
compared with the incidence among white populations. However, less is known about the incidence 
of diabetes among persons with IFG and normal NFG. In addition to the Hoorn study in a Dutch 
population and a cohort study in Hong Kong Chinese42,43, a Finnish study, the Bruneck study in an 
Italian population and the population-based surveys in Mauritius, also reported the incidence of 
type 2 diabetes from different stages of glucose during the follow-up44-46 (Table 2.6). In the Hoorn 
study, the Finnish study, and the Bruneck study, the individuals with both IGT and IFG combined 
had the highest incidence of diabetes, while subjects with isolated IFG appeared to have a lower 
incidence than those with isolated IGT, except for those participants in the Bruneck study.  
However, the Bruneck study defined incident diabetes as FPG ?7.0 mmol/l or clinical diagnosis. 
This might explain why subjects with isolated IFG had a higher incidence of diabetes instead of 
those with isolated IGT in the study. 
Table 2.6 Incidence of type 2 diabetes in five studies based on different stages of glucose
Author (Population) n Category of glycemic status Period Mean follow-up duration (years) Cumulative Incidence (%) Incidence rate
per 1000 person years 
de Vegt et al. 2001 (Dutch)  
1125 NFG and NGT 6.47 4.5 7.0 
106 IFG and NGT 6.42 33.0 51.4 
80 NFG and IGT 5.83 33.8 57.9 
31 IFG and IGT 5.75 64.5 112.2 
Ko et al. 2001 
(Hong Kong Chinese) 
  
 264 NFG  0.87-8.54 4.9  
 55 IFG  0.87-8.54 25.5  
Qiao et al. 2003 (Finland)  1987-1997  
2129 NFG and NGT 2.0 
104 IFG and NGT 4.6 
322 NFG and IGT 10.8 
38 IFG and IGT 49.9 
Soderberg et al. 2004  
(Mauritius) 
  
NGT     
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 1176 (M)  1987-1992   14.6 (M)
 1268 (F)     5.8 (F)
 1169 (M)  1992-1998   12.9 (M)
 1413 (F)     10.3 (F)
IFG     
 92 (M)  1987-1992   54.1 (M)
 57 (F)     35.1 (F)
153 (M)  1992-1998  60.5 (M) 
100 (F)  74.7 (F) 
IGT     
221 (M)  1987-1992  60.7 (M) 
379 (F)  47.9 (F) 
227 (M)  1992-1998  119.6 (M) 
435 (F)  81.0 (F) 
Bonora et al. 2004 (Italian)  1990-2000  
710 NFG and NGT 4.3 
55 IFG and NGT 37.0 
53 NFG and IGT 17.0 
19 IFG and IGT 49.2 
M: male; F: female
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2.7 MetS and incident diabetes 
2.7.1 Components of MetS and incident diabetes  
There have been many prospective studies on the association between the components of MetS, e.g. 
IFG, IGT, insulin resistance, overweight/obesity, hypertension, and dyslipidaemia, and incident 
diabetes. Among these individual risk factors, the most important and consistent are IGR, obesity, 
and insulin resistance. However, studies in relation to prediction of other risk factors such as 
hypertension and dyslipideamia, to incident diabtes showed conflicting results due to differences in 
covariates or definition of diabetes. Little information is available on whether or not 
microalbuminuria is an independent predictor of incident diabetes.  
2.7.1.1 Impaired glucose regulation 
Although there is evidence that other factors such as age, family history of diabetes, waist-to-hip 
ratio (WHR), BMI, blood pressure (BP), and lipid levels are independently associated with the 
development of diabetes, none taken singly is as good at discriminating who will progress to 
diabetes as measuring glucose levels. IGT had been found to be a strong predictor of incident 
diabetes before IFG was also created as a new category of abnormal glucose metabolism41 47. Since 
the WHO approved new diagnostic criteria for the diagnosis of diabetes in 1999, the Hoorn Study 
has demonstrated that after adjustment for age, sex, and follow-up duration, the relative risks (RR) 
of incident diabetes were 10.0 and 10.9 for isolated IFG and isolated IGT, respectively, compared to 
normal glucose levels, while combined IFG and IGT were associated with a 39.5-fold increased risk 
of future diabetes42. Furthermore, another study showed that the sensitivity for predicting 
progression to type 2 diabetes was 26% for IFG and 50% for IGT. Only 26% of subjects that 
progressed to type 2 diabetes were predicted by their IFG values, but a further 35% could be 
identified by also considering IGT. The results implicate that IGT identifies more high-risk subjects 
than IFG48.
2.7.1.2 Obesity 
Overweight, obesity, or weight gain has shown to be an important risk factor for the development of 
type 2 diabetes. In a cohort study of 51,529 U.S. male health professionals aged 40-75 years, a 
strong positive association between overall obesity as measured by BMI and risk of incident 
diabetes was observed during the 5-year follow-up49. In this study men with a BMI of at least 35 
kg/m2 had a multivariate RR of 42.1, compared to men with a BMI of less than 23 kg/m2 (P<0.001). 
Fat distribution, measured by WHR, was a good predictor of diabetes only among the top 5%, while 
WC was positively associated with the risk of diabetes among the top 20% of the cohort. Recently, 
the Health Professionals Follow-Up Study of 27,270 American men reported that both overall and 
abdominal adiposity strongly and independently predicted the risk of type 2 diabetes, and WC was a 
better predictor than WHR50. In a national cohort of 8,545 U.S. adults from the National Health and 
Nutrition Examination Survey Epidemiologic Follow-up Study, 5- < 8 kg, 11- < 20 kg and over 20 
kg weight gains were associated with a 2.1-fold, 2.6-fold, and 3.9-fold increased risk of incident 
21
diabetes during the 9-year follow-up, respectively, compared with participants whose weights 
remained relatively stable51. The authors found no evidence that the results differed by age, sex, or 
race. They estimated that the population attributated risk was 27% for weight increases of 5 kg or 
more. Of an age- and sex-stratified random sample of 1,000 individuals aged 40-79 years, the 
Bruneck Study confirmed that BMI was a predictor of incident diabetes, independently of other 
components of MetS such as IFG, IGT, insulin resistance, hypertension, and dyslipidaemia45.
2.7.1.3 Insulin resistance  
In a prospective study of Pima Indians the 90th percentile of fasting insulin level was associated 
with a 15.8-fold increased risk of incident diabetes compared with the 10th percentile adjusted only 
for gender52. The San Antonio Heart Study (SAHS) of Mexican Americans and non-Hispanic 
whites reported that after adjustment for age, sex, ethnicity, BMI, and centrality, the top quartile of 
fasting insulin levels were significantly associated with a 2.3-fold increased risk of the development 
of diabetes over an 8-year follow-up16. Using combined prospective data from the SAHS, the 
Mexico City Diabetes Study (MCDS), and the Insulin Resistance Atherosclerosis Study (IRAS), the 
authors found that in adjusting for age, sex, systolic blood pressure (SBP), HDL-cholesterol and 
BMI models with all subjects pooled as well as separately glucose tolerance status (NGT versus 
IGT), study and ethnic group, insulin resistance predicted type 2 diabetes independently of these 
covariates. However, there were substantial differences between published IR indices in the 
prediction of diabetes. Among the indices of insulin resistance such as fasting insulin, homeostasis 
model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index 
(QUICKI), insulin sensitivity index (ISI), and 2-h insulin/2-h glucose (I2/G2), Gutt et al.'s ISI at 0 
and 120 min (ISI (0,120)) displayed the strongest prediction53. After adjustment of age, sex, 
alcohol, smoking, physical activity, IFG, IGT, BMI, hypertension, and dyslipidaemia, the Bruneck 
Study also showed that insulin resistance measured as HOMA predicted the development of 
diabetes independently.  
2.7.1.4 Dyslipidaemia 
The results from the Norwegian population-based Finnmark Study showed that HDL cholesterol 
was inversely related to incident diabetes in women, but not in men, controlling for other risk 
factors such as BMI, diastolic blood pressure (DBP), glucose and ethnicity. However, triglycerides 
were positively related to the incidence of diabetes in men and women adjusted for age54. The 
MONICA (Monitoring of Trends and Determinants in Cardiovascular Disease) Augsburg Cohort 
Study also displayed an inverse association between HDL-cholesterol and incident diabetes in both 
genders55. In a prospective study in Swedish women, triglycerides (TG) carried a steeply increased 
multiple-adjusted (adjusted for age, physical activity, BMI, SBP and total cholesterol) risk for 
incident diabetes with hazard ratio 3.0 already at TG 1.0-1.4 mmol/l, 3.7 at TG 1.5-1.9 mmol/l and 
4.5 at TG ?2.0 mmol/l, compared with TG < 1.0 mmol/l (P<0.001)56. However, the Bruneck Study 
did not demonstrate a significant association between dyslipidaemia and incident diabetes in 
multivariate logistic regression analysis (adjusted for age, sex, alcohol, smoking, physical activity, 
IFG, IGT, BMI, insulin resistance, and hypertension).
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2.7.1.5 Hypertension 
A questionnaire survey in the Netherlands among 5,700 men and women aged 20 to 65 showed that 
after adjusting for age and BMI, SBP and DBP were still associated with the incidence of diabetes 
(defined as the current use of oral hypoglycemic drugs and /or insulin) in men. For women, only the 
relative risk associated with the use of diuretics remained statistically significant57. The MONICA 
Augsburg Cohort Study demonstrated that in multivariate analysis (controlling for age, BMI, HDL 
cholesterol, uric acid, alcohol intake, physical activity and survey), SBP predicted the development 
of diabetes in men also55. A study reported that the Swedish women whose SBP was at least 145 
mmHg had a risk to diabetes over 2.2 times that of women with a SBP of less than 145 mmHg, after 
adjusting for age, BMI, physical activity, TG, and total cholesterol56. However, the Bruneck Study 
displayed that after further control for alcohol, smoking, physical activity, IFG, IGT, BMI, insulin 
resistance, and dyslipidaemia, there was no association between hypertension and incident diabetes. 
However, hypertension was associated with a 2.3-fold increased risk of future diabetes adjusted for 
only age and sex.   
2.7.1.6 Microalbuminuria 
Microalbuminuria is a well-established marker for incipient nephropathy in patients with diabetes58.
In addition, microalbuminuria is associated with increased CVD in both diabetic and non-diabetic 
subjects59,60. Previous studies reported that microalbuminuria in non-diabetic subjects was 
associated with MetS, and suggested that microalbuminuria might be a feature of MetS61. However, 
multiple logistic regression analyses in diabetic and non-diabetic subjects separately showed that 
microalbuminuria was independently associated only with hypertension, diabetes and WHR, but not 
with other variables of MetS in a Caucasian population. It is therefore likely that microalbuminuria 
is a complication of hypertension and diabetes, and not an integral part of MetS62. Thus far, there 
has been only a Finnish study on the association between the microalbuminuria factor derived from 
factor analysis and incident diabetes63. However, the microalbuminuria factor did not predict 
incident diabetes in the study.    
2.7.2 The WHO-defined or the NCEP-defined MetS and incident diabetes 
There have been three prospective studies on association between the WHO-defined or the NCEP-
defined MetS and incident diabetes64-66. These results showed that both the WHO-defined and the 
NCEP-defined MetS were predictors of incident diabetes. The WHO-defined MetS seemed to be 
more sensitive for predicting the development of diabetes than the NCEP-defined MetS, except for 
the inverse results from the SAHS. However, IGT was not included as a component of the WHO-
defined MetS in the SAHS (Table 2.7.2). 
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Table 2.7.2 Three studies on comparisons of ability of the NCEP-defined or WHO-defined MetS to predict type 2 
diabetes  
Author (year) Duration of 
follow-up 
(years) 
Population   Results  
   Odds Ratio  Sensitivity  
   NCEP-defined 
MetS 
WHO-defined  
MetS
NCEP-defined  
MetS
WHO-defined  
MetS
Laaksonen et al. 
(2002) 
4  1005 middle-aged 
Finnish men 
8.0 8.8 41 67 
Hanson et al. 
(2002) 
4.1  890 Pima Indians 
aged at least 20 
years 
2.09 (1.49-2.92) † 3.58 (2.56-5.00) † 43 58 
Lorenzo et al. 
(2003) 
7-8  1734 Mexican 
Americans and 
Hispanic whites 
aged 25-68 years 
3.30 (2.27-4.80)  53 43* 
†Incidence rate ratio (IRR); *IGT was excluded as a component of the WHO-defined MetS 
2.8 Mechanism of MetS 
Although the underlying mechanism of the syndrome is not completely understood, environmental 
factors such as obesity, physical inactivity, and unbalanced total energy intake, together with still 
largely unknown genetic triggers, increase susceptibility to the syndrome67,68.
2.8.1 Environmental factors
2.8.1.1 Birth weight, childhood obesity, smoking, alcohol, coffee, tea, social status and age 
Birth weight 
Low birth weight and thinness at birth are correlated with abnormal glucose tolerance, dyslipidaemia 
and hyperinsulinaemia in later adulthood69-71. In 34 studies of more than 66,000 people, almost all 
results showed that an increase in birth weight was associated with a fall in blood pressure, and there 
was no exception to this in the studies of adults which included total nearly 8,000 men and women72.
The odds ratio (OR) for diabetes, after adjusting for current body mass, was 3.8 in men whose birth 
weights were less than 2.5 kg compared with those who weighed 3.2-3.9 kg73. Of 64-year-old men 
whose birth weights were 2.95 kg or less, 22% had MetS. Their risk of developing MetS was more than 
10 times greater than that of men whose birth weights were more than 4.31 kg74.   
Childhood obesity   
It has been suggested that the origins of adulthood risk of CVD and type 2 diabetes can be related to 
somatic growth as a child, not necessarily to intrauterine growth. In westernized countries, the relative 
proportion of underweight newborn children is decreasing; thus, considering the entire population’s 
low birth weight has lost its theoretical role in the aetiology of type 2 diabetes and CVD75.
Conversely, as obesity is known to be increasing in the industrialized countries among all age groups, 
the association between weight gain in childhood and MetS in adulthood is more than noteworthy. 
The risk of MetS was lower among obese adults who had not been obese as children compared to 
obese adults who had also been obese as children76. A population study in Finland found that among 
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obese children at the age of seven (BMI in the highest quartile), the OR for MetS in adulthood was 
4.4 (95% CI 2.1-9.5) as compared to the other children (the three other quartiles combined). After 
adjustment for age, sex and current obesity, the risk of the syndrome still was 2.4 (95% CI 2.1-9.5)75.
Smoking
The results of 54 published studies displayed that overall, smokers had significantly higher serum 
concentrations of cholesterol, TG, VLDL cholesterol, and low-density lipoprotein (LDL) 
cholesterol, and lower serum concentrations of HDL cholesterol and apolipoprotein AI compared 
with non-smokers77. It was shown that the measures of insulin sensitivity were significantly lower 
in smokers when the degree of insulin-mediated glucose uptake (insulin sensitivity) was compared 
in smoking and non-smoking men78. Among those who smoked at least two packs per day at 
baseline, men had a 45% higher diabetes rate than men who had never smoked; the comparable 
increase for women was 74%. Quitting smoking reduced the rate of diabetes to that of non-smokers 
after five years in women and after ten years in men79. Recently, a study on Koreans reported that 
smoking (more than 20 pack-years) was associated with a 1.4-fold and 1.9-fold increased risk of 
high triglycerides and low HDL-cholesterol. The relative risk of developing NCEP-defined MetS in 
smokers (more than 20 pack-years) was 1.9-fold higher compared with non-smokers although there 
was no significant difference in blood pressure in the smoking group80.
Alcohol
Epidemiological studies have shown an association between light to moderate alcohol consumption 
and reduced risk of MetS and developing type 2 diabetes. Some of the biological mechanisms 
reported to explain this observation include an improvement of the lipid profile, especially HDL 
cholesterol81 and increasing insulin sensitivity82,83.  Recently, a cross-sectional analysis on data from 
8,125 participants in the U.S. showed that after adjustment for age, sex, race/ethnicity, education, 
income, tobacco use, physical activity, and diet, subjects who consumed 1-19 and ? 20 drinks of 
alcohol per month had ORs for the prevalence of the NCEP defined- MetS of 0.65 and 0.34, 
respectively (P < 0.05), compared with current nondrinkers. These findings were particularly 
noteworthy for beer and wine drinkers. Alcohol consumption was significantly and inversely 
associated with the prevalence of the following four components of MetS: low serum HDL 
cholesterol, elevated serum triglycerides, high WC and hyperinsulinemia84. Although alcohol 
consumption had a significant inverse relation with the OR for low HDL cholesterol in all alcohol 
groups, and lower alcohol consumption had a favorable effect on MetS, an increasing dose-response 
relation was found between alcohol consumption and the OR for MetS in a Korean population. In 
this population, heavy alcohol consumption of at least 30 g per day was associated with 
significantly higher ORs for high blood pressure, and high triglycerides in men and high fasting 
blood glucose and high triglycerides in women. ORs for the NCEP-defined MetS and its 
components tended to increase with increasing alcohol consumption85.
Coffee  
Intake of coffee is often reported as a cardiovascular risk factor86. However, no clear association 
between coffee and the risk of hypertension, total cholesterol, LDL-C levels, myocardial infarction, or 
other cardiovascular diseases has been demonstrated87,88. Furthermore, coffee consumption was related 
to improved insulin sensitivity89. Several studies on Dutch, Japanese, American, and Swedish 
population have shown that coffee consumption was associated with a substantially lower risk of 
clinical type 2 diabetes90-93, although the reasons for this risk reduction remain unclear. A Finnish study 
reported that in 6,974 Finnish men and 7,655 women aged 35 to 64 years during a mean follow-up of 
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12 years, after adjustment for confounding factors (age, study year, BMI, SBP, education, occupation, 
commuting, leisure-time physical activity, alcohol and tea consumption, and smoking), the hazard 
ratios of diabetes associated with the amount of coffee consumed daily (0-2, 3-4, 5-6, 7-9, ?10 cups) 
were 1.00, 0.71 (95% CI, 0.48-1.05), 0.39 (0.25-0.60), 0.39 (0.20-0.74), and 0.21 (0.06-0.69) in 
women, and 1.00, 0.73 (0.47-1.13), 0.70 (0.45-1.05), 0.67 (0.40-1.12), and 0.45 (0.25-0.81) in men, 
respectively. In both sexes combined, the multivariate-adjusted inverse association was significant and 
persisted when stratified by younger and older than 50 years; smokers and non-smokers; healthy 
weight, overweight, and obese participants; alcohol drinkers and non-drinkers; and participants 
drinking filtered and nonfiltered coffee94.
Tea
The results of experimental studies have shown the protective effect of tea in improving lipid and 
glucose metabolism and enhancing insulin sensitivity95-97. A study from Taiwan showed that Oolong 
tea significantly decreased plasma glucose (from an initial concentration of 229±53.9 to 162.2±29.7 
mg/dl), whereas water did not (from 208.7± 61.0 to 232.3±63.1 mg/dl). Fructosamine concentration 
decreased significantly (from 409.9± 96.1 to 323.3±56.4 ?mol/l with the tea treatment) but did not 
change significantly with water treatment (from 368.4±85.0 to 340.0±76.1 ?mol/l). This study supports 
the concept that Oolong tea is effective in lowering the plasma glucose levels of subjects who have 
type 2 diabetes98. However, the epidemiological evidence, data released from recent the cohort study 
of diverse countries (i.e. the Netherland, the U.S., Sweden and Finland), failed to show the same 
association as coffee on the risk of type 2 diabetes92-94.
Socioeconomic status
Individual components of MetS have been related to socioeconomic factors. Low socioeconomic 
position is associated with increased risk for the metabolic clustering of risk factors99,100. The Whitehall 
II study of 4,978 men and 2,035 women showed the age-adjusted OR for having clustering of MetS 
comparing the lowest with the highest employment grade was 2.2 (95% CI 1.6-2.9) in men and 2.8 
(1.6-4.8) in women adjusting for menopausal status (Brunner et al. 1997). In Swedish women, after 
adjustment for age, the lowest (? 9 years) education was associated with a 2.7-fold increased risk of the 
presence of MetS compared with the highest (college/university) education. This association persisted 
after controlling for menopausal status, family history of diabetes, and behavioral risk factors101. A 
Korean study also found that RR of the NCEP-defined MetS was 2.0 in Koreans with no or an 
elementary school education versus university graduation adjusted for age, sex, BMI, and exercise80.
Age
Aging is associated with increased insulin resistance and declining glucose tolerance, an increase in 
visceral adipose tissue, and a trend towards increased blood pressure102-104. Epidemiological studies 
have demonstrated a marked increase in prevalence of MetS with age105,106. Park et al. found that the 
prevalence of MetS increased steeply after the third decade and reached a peak in the sixth decade for 
men and in the seventh decade for women. In some ethnic groups prevalence rates declined in the 
eighth decade for men and women106.
2.8.1.2 Diet  
Dramatic changes in the prevalence or incidence of type 2 diabetes have been observed in communities 
where there have been major changes in the type of diet consumed, from a traditional indigenous diet to 
a typical ‘Western’ diet, e.g. Pima Indians in Arizona, Micronestans in Nauru and Aborigines in 
Australia107-109. For the Pima Indians in Arizona, the transition from an agrarian to a modern society 
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was associated with the consumption of increasing amounts of dietary fat, decreasing amounts of 
dietary carbohydrates, and a deterioration in insulin sensitivity110. Most developing countries have 
experienced a shift in the overall structure of its dietary pattern with related disease patterns over the 
last few decades.  Major dietary change includes a large increase in the consumption of fat and added 
sugar in the diet, often a dramatic increase in animal food products contrasted with a fall in total cereal 
and fiber intake111. The traditional lifestyle of Chinese has changed markedly over two decades with 
rapid development of its economy. According to 4th CNHS, fat consumption in the diet increased from 
28% in 1992 to 35 % of total energy intake in 2002 in urban areas, while carbohydrate consumption 
decreased from 57% in 1992 to 47% of total energy intake in 2002. In contrast, the analogous values of 
fat intake were 19%, 28% (carbohydrate: 72%, 61%), respectively, in rural areas. In developed 
countries, i.e. in the U.S., a demographic shift toward an overall positive energy balance that has 
increased over the past few decades has been observed. It has been estimated that Americans consumed 
an average of 340 kcal/day more in 1994 than in 1984 and 500 kcal/day more than in 1977112.
Animal models have shown high-fat diets and increased levels of non-esterified fatty acids (NEFAs) to 
cause insulin resistance in hepatocytes, adipose cells and skeletal muscle in vitro113-115, and to be involved 
in the pathogenesis of type 2 diabetes116. In humans, intakes high in total fat and saturated fat, and intakes 
low in carbohydrates or starches and fiber, correlated with higher fasting insulin concentrations117-119.
High total fat intake has also been associated with a lower insulin sensitivity index120. In both Pima 
Indians and Caucasians, glucose-mediated glucose disposal, beta-cell function, and glucose tolerance 
deteriorated in the modern diet (carbohydrate, 30%; fat, 50%; protein, 20%) 121. A high fat intake has 
been shown to predict development of IGT in a group of healthy subjects and progression from IGT to 
type 2 diabetes in a group of subjects with IGT122,123. Higher proportions of saturated fatty acids in serum 
lipids/muscle phospholipids have been associated with higher fasting insulin levels, lower insulin 
sensitivity, and a higher risk of developing type 2 diabetes124,125. A high intake of trans-fatty acids was 
also associated a higher risk of diabetes126. However, higher vegetable fat (unsaturated fat) and 
polyunsaturated fatty acids (PUFAs) intake have been associated with a lower risk of type 2 diabetes, as 
well as lower fasting and 2-hour glucose concentrations127,128. A whole-grain diet resulted in higher
concentrations of insulin sensitivity and lower concentrations of fasting insulin than did a refined-grain 
diet129, while increasing intakes of refined carbohydrates (corn syrup) concomitant with decreasing 
intakes of fiber paralleled the upward trend in the prevalence of type 2 diabetes130.
2.8.1.3 Physical inactivity  
Low levels of physical activity are associated with most components of MetS, especially with an 
increased risk of obesity. Advances in technology and transportation have reduced the need for 
physical activity in daily life. Labor-saving devices have eliminated many of back-breaking tasks of 
agricultural- and industrial-sector occupations and reduced the time it takes to complete them. The 
appeal of television, electronic games, and computers has increased the time spent in sedentary 
pursuits among children and adults131. The average person in England watched over 26 hours of 
television a week in the 1990s, compared with 13 hours in the 1960s132. In the United States the 
prevalence of obesity increased by 2% for each additional hour of television viewed among 12- 
to17-year-old adolescents133. The adjusted odds of overweight incidence were 8.3 times greater for 
youths watching more than 5 hours of television per day compared with those watching for 0 to 2 
hours, and more than 60% of overweight incidence can be linked to excess television viewing 
time134. A cohort study (1989 to 1997) from 2,485 adults aged 20 to 45 years from eight provinces 
in China found that after adjustment of age, work, leisure activity, energy intake, smoking status, 
alcohol consumption, income, education, household ownership of a computer and TV, and urban 
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residence, the odds of being obese were 70% higher for men and 85% higher for women in 
households who owned a motorized vehicle compared with those who did not own a vehicle135.
Insulin resistance plays a central role in MetS, being associated with most of the other metabolic 
abnormalities in the syndrome136. Physical training has mostly been shown to improve insulin 
sensitivity in healthy humans regardless of age, in obese non-diabetic subjects, and in patients with 
type 2 diabetes 137,138. Exercise also has pronounced effects upon the metabolism of glucose because 
exercising muscle may increase glucose uptake 7- to 20-fold139. The Finnish Diabetes Prevention 
Study (DPS) and the Diabetes Prevention Program (DPP) in the United States revealed a 58% 
reduction in the risk of diabetes in high-risk subjects who enhanced physical activity140,141. The DPS 
also found that the intervention group had a significant decrease in serum concentrations of 2-h 
postload insulin and TG, and a marked increase in HDL colesterol levels compared with the control 
group. Physical activity has been positively associated with HDL cholesterol concentrations among 
men and women142,143. A cross-sectional survey in an urban area of the city of Tianjin, China, found 
that daily walking or cycling to and from work was inversely associated with serum total cholesterol, 
LDL cholesterol, and TG concentrations among men, and was positively associated with HDL 
cholesterol concentrations among women as compared to traveling to and from work by bus144. A 
meta-analysis of 25 longitudinal studies examining the antihypertensive effect of exercise showed 
reductions in resting SBP and DBP of 11 and 8 mmHg, respectively. However, the decrement in BP 
evoked by exercise was not sufficient to produce normotension in many studies145. The overall 
impression from the published studies is that regular exercise training provides a modest 
antihypertensive effect, and the use of exercise therapy for the treatment of hypertension is most 
beneficial in the early stages of hypertension, as well as for the prevention of hypertension146-148.
2.8.1.4 Obesity 
Obesity is becoming increasingly common worldwide due to adoption of a more sedentary lifestyle 
and an increased intake of energy-rich diets149. It is well accepted that obesity, as the core of MetS, 
promotes glucose intolerance, insulin resistance, hypertension, and dyslipidaemia, and is associated 
with the development of type 2 diabetes and coronary heart disease150. The prevalence of serious 
obesity doubled in Britain between 1980 and 1991 and is continuing to increase151. In the United 
States, the age-adjusted prevalence of obesity was 30.5% in 1999-2000, compared with 22.9% in 
1988-1994. The prevalence of overweight also increased during this period from 55.9% to 64.5%. 
Extreme obesity (BMI ? 40) also increased significantly in the population, from 2.9% to 4.7%152. A 
gradient of increasing prevalence of abdominal obesity (WC ?102cm in men; ?88cm in women) from 
1960 to 2000 was also observed in men and women in the U.S.. In men, the overall age-adjusted 
prevalence of abdominal obesity was 12.7%, 29%, and 38.3% in 1960–1962, 1988–1994 and 1999–
2000, respectively. In women, the analogous values were 19.4%, 38.8% and 59.9%, respectively. The 
4th CNHS showed that the prevalence of obesity (BMI ?30) and overweight (BMI ?25) has increased 
by 97% and doubled, respectively, between 1992 and 2002 in Chinese adults153.
Obesity and weight gain are important determinants of clustering of the individual traits of MetS. A 
study in Hong Kong Chinese men showed, after adjustment for age, smoking, and insulin 
resistance, increasing BMI and WHR remained closely associated with increased concentrations of 
TG and apo B, increased ratios between LDL and HDL (LDL/HDL) cholesterol, and between apo B 
and LDL (apo B/LDL), increased fasting and 2-h plasma glucose and insulin, as well as decreased 
concentrations of HDL, HDL2 and apolipoprotein A-I (apo A-I)154.   The relationship between 
insulin sensitivity and overall obesity is well established155. Furthermore, visceral abdominal tissue 
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(VAT) and subcutaneous abdominal tissue (SAT), which were measured from computed 
tomography scans performed at the L4/L5 vertebral region, and their joint interactions were each 
inversely and significantly associated with ISI, adjusting for age, sex, ethnicity, and BMI. SAT, but 
not VAT, was positively associated with acute insulin response (AIR). Thus, fat distribution is an
important determinant of both insulin resistance and insulin secretion156. The NHANES II (National 
Health and Nutrition Examination Survey II) study found obese women to be four times more likely 
to develop diastolic hypertension than non-obese women157. In the Framinghan population, weight 
gain had a stronger relationship with blood pressure in males than in females158. There appears to be 
a consensus that obesity is an important risk factor of type 2 diabetes159. Besides, researchers 
reported that the RR for IGT increased more than 4-fold among obese subjects, compared with 
normal-weight subjects in a Swedish population160. In an Italian population, obese subjects had a 
frequency of IGR three times that of subjects with normal weight161.
2.8.2 Genetic factors  
Racial differences in risk162, familial clustering of case163, twin studies164 have provided grounds for the 
argument that genetic factors contribute to MetS. 
2.8.2.1 Candidate gene studies 
There is clearly a multitude of genes responsible for the regulation of the manifold phenotypes that 
comprise MetS. Among these genes contributing to MetS, genes regulating lipolysis and 
thermogenesis still remain prime candidates165-168 (Table 2.8.2.1).  
In addition, the genetic basis of MetS as a composite phenotype has been systematically explored. 
Polymorphisms in eight genes, including low density lipoprotein receptor (LDLR), glucan (1,4-
alpha)-branching enzyme 1 (GBE1), interleukin 1 receptor, type 1 (IL1R1), transforming growth 
factor-{beta}1 (TGFB1), interleukin 6 (IL6), collagen, type V, alpha 2 (COL5A2), E-selectin (SELE), 
and hepatic lipase (LIPC) have been found to be associated with the NCEP-defined MetS169.
Table 2.8.2.1 Candidate genes related to MetS (in alphabetical order) 
Adiponectin Insulin receptor 
Angiotensinogen Insulin receptor substrate-1 (IRS-1) 
? 2- and ?3- adrenergic receptors Leptin and leptin receptor 
CD36 Insulin  
Cytokine interleukin-6 (IL-6) Insulin receptor 
Cytokine tissue necrosis factor alpha (TNF-?) Peroxisome proliferator-activated receptor gamma 
(PPAR?)
Glucocorticoids Plasminogen activator inhibitor-1 (PAI-1) 
Glycogen synthase Plasma cell membrane glycoprotein 1 (PC-1) 
11? hydroxysterol dehydrogenase type 1 (11 ? HSD-1) Sterol regulatory element binding protein-1C (SREBP-1C) 
Insulin Uncoupling proteins 
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2.8.2.2 Genome-wide scans 
Genome scans have identified various chromosomal regions with suggestive linkage to clusters of 
specific metabolic traits in Caucasian families: a quantitative trait locus (QTL) on chromosome 3 
(3q27) strongly linked to six traits such as BMI, WC, hip circumference, weight, insulin, 
insulin/glucose, and QTL on chromosome 17 (17p12) exhibited significant linkage with plasma 
leptin levels170. A susceptibility locus for coronary heart disease on chromosome 16p13 and 
replicates linkage with MetS on 3q27 were also observed in Indo-Mauritians171. In whites, 
promising evidence for linkage was found for MetS phenotypes (2 markers on 10p11.2, a marker on 
19q13.4), while in blacks promising linkage was found for MetS phenotypes on 1p34172.
2.9 Prevention of MetS and diabetes  
The previous clinical trials of lifestyle-intervention in Sweden173, China174, Finland140, and the 
United States141 demonstrated that the combination of weight loss, diet intervention and increased 
physical activity could significantly decrease the development of type 2 diabetes in high-risk 
individuals. The four studies provide the most dramatic evidence of the beneficial effects of 
lifestyle intervention on prevention of diabetes and MetS.
2.9.1 Lifestyle intervention  
In the Da Qing IGT and Diabetes Study, for subjects assigned to the diet-only intervention, the 
participants with BMI ? 25 kg/m2 were encouraged to reduce their calorie intake so as to gradually 
lose weight at a rate of 0.5-1.0 kg per month until they achieved a BMI of 23 kg/m2. The 
participants with BMI < 25 kg/m2 were prescribed a diet containing 25-30 kal/kg body weight, 55-
65% carbohydrate, 10-15% protein, and 25-30% fat. For subjects assigned to the exercise-only 
intervention, the participants were taught and encouraged to increase the amount of their leisure 
physical activity by at least 1U/day, i.e., faster walking at least 20 minutes per day and by 2 U/day 
if possible for those < 50 years of age with no evidence or CVD or arthritis. For subjects assigned to 
the diet-plus-exercise intervention, the participants received instruction and counseling for both diet 
and exercise interventions that were similar to those for the diet-only and the exercise-only 
intervention group. The diet-plus-exercise intervention was associated with a 42% reduction in risk 
of incident diabetes174. In the DPS, 25-47% of the subjects in the intervention group succeeded in 
achieving the goals of the lifestyle intervention during the first year, which were a reduction in total 
intake of fat to less than 30% and in the intake of saturated fat to less than 10%, an increase in fiber 
intake to at least 15 g per 1000 kcal, a weight reduction of at least 5% of initial body weight, and 
moderate excise for at least 30 minutes per day. As a result, the risk of diabetes was reduced by 
58% in the intervention group after four years. In contrast, only 11-26% of the subjects in the 
control group achieved these goals. The DPP tested a goal of intervention including physical 
activity of moderate intensity, such as brisk walking for at least 150 minutes per week, a reduction 
in total intake of average fat to less than 32%, and a weight reduction of at least 7% of initial body 
weight.  There was also a 58% reduction in the rate of progression in the lifestyle intervention 
group in the study (Table 2.9.1).
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2.9.2 Pharmacologic therapies 
Given the difficulty in changing lifestyle, and the probable limits of its efficacy in many 
individuals, it could be argued that treatment of MetS would be a drug(s) that could significantly  
enhance insulin sensitivity, as well as the other manifestations of MetS.  Although metformin does 
not seem to act by directly improving insulin sensitivity, there is evidence that metformin 
administration can lower circulating insulin levels and improve glucose and lipid metabolism in 
patients with characteristics of MetS175. The findings of the DPP, where a 31% reduction in the rate 
of progression was observed in patients taking metformin (850mg twice daily), provide evidence 
that metformin can also delay progression of IGT to diabetes.  Thus, the drug may offer potential 
benefit for treatment of MetS. In addition, acarbose can decrease resistance to insulin in patients 
with IGT, and significantly decrease the postprandial rise in plasma glucose176. The results of the 
STOP-NIDDM Trial showed that treating IGT patients with acarbose (100mg three times daily) 
was associated with a 49% reduction in the development of cardiovascular events, a 34% reduction 
in the incidence of new cases of hypertension and a 25% reduction in the progression of type 2 
diabetes compared with those taking placebo177,178. In the troglitazone in the prevention of diabetes 
(TRIPOD) trial, the average incidence of diabetes was 12.1% in women randomized to placebo and 
5.4% in women taking the PPARγ agonist troglitazone during a median follow-up of 30 months 179.
Given the importance that obesity plays in the development of MetS in susceptible individuals, 
pharmacological treatment of obesity may play an important role in the management of overweight 
individuals with MetS. If overweight/obese patients with MetS cannot lose weight with simple 
caloric restriction, both orlistat and sibutramine have been shown to be more effective than diet 
alone in the treatment of obesity. Furthermore, administration of both drugs to appropriately 
selected individuals has been shown to result in attenuation of the manifestations of MetS180. In the 
absence of evidence that there is one drug capable of addressing the entire cluster of abnormalities 
associated with MetS, pharmacological treatment at this point is by necessity directed to the 
individual manifestations of MetS, i.e. hypertension, dyslipidaemia, etc., which persist despite 
appropriate changes in lifestyle.  Patients with MetS also have elevations in fibrinogen and other 
coagulation factors leading to a prothrombotic state. Thus aspirin may be beneficial for primary 
prevention in these patients181.
Table 2.9.1 The goals of lifestyle intervention in Da Qing IGT and Diabetes Study, DPS and DPP 
*BMI?23 
   Goals for the lifestyle intervention group 
Study  Duration of  
follow-up  
(year) 
Reduction in 
risk of diabetes 
(%) 
Weight reduction 
(%) 
Fat intake of 
energy intake 
(%) 
Saturated-fat intake  
of energy intake  
(%) 
Fiber intake 
(g/1000kcal) 
Moderate 
exercise
(min/week) 
Da Qing 6 42 ?23* 25-30   ?140 
DPS  4 58 >5 <30 <10 ≥15 ?210 
DPP  2.8 58 ≥7 <32   ?150 
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3. AIMS OF THE STUDY 
The overall aim was to obtain new information about the relationship between MetS and incident 
diabetes in a Chinese population. The follow-up data collected in the Beijing Project survey 
provides unique possibilities for such an evaluation. More specifically, the aims of the study were to 
address the following questions: 
• Are the WHO, EGIR, NCEP, AACE and IDF definitions of MetS sensitive for predicting type 
2 diabetes in Chinese men and women? 
• Which state of impaired glucose homeostasis at baseline best predicts the conversion to type 2 
diabetes? 
• How do the major components of MetS defined by factor analysis relate to each other and to 
the development of diabetes in the Chinese population? 
• Are there differences in changes in the features of MetS during the transition of glucose 
tolerance, and what are the relative contributions of these changes to the development of 
impaired glucose regulation or type 2 diabetes? 
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4. MATERIALS AND METHODS 
4.1 The second National Diabetes Survey  
China has 31 administrative provinces, cities, and autonomous areas with a total population of 1.3 
billion people. The first national diabetes survey was carried out in 1980. The second National 
Diabetes Survey, involving a population of 250,000 aged 25 and older in 19 provinces and areas, 
was launched in 1994. The survey included cities and rural areas in the eastern, southern, western, 
northern parts of China. A total of 224,251 subjects aged 25 and over participated in the survey 
(89.7%), of whom 213,515 (men 113,002; women 100,513) were aged 25-64 years. In April 1994, a 
workshop was held in order to standardize the protocol and methodology, and a three-day training 
course took place for the investigators in each location before the baseline survey. The results from 
the previous Da Qing IGT and Diabetes Study on 2,692 subjects with 2-h post-prandial plasma 
glucose 6.67-7.70 mmol/l showed 9 cases of diabetes (0.3%) and 31 cases of IGT (1.2%) based on 
the WHO - 1985 criteria37. Thus, the subjects with 2-h post-prandial capillary glucose < 6.67 
mmol/l would be expected to have an extremely low percentage of diabetes or IGT. In this context, 
a fingerstick pre-screening using a One Touch II glucose meter after a breakfast containing at least 
80g of carbohydrates was used in the present screening survey in order to maximize the yield of 
abnormal glucose tolerance at 75g oral glucose tolerance test (OGTT). In the participants whose 2-
hour post-prandial capillary blood glucose was ≥6.67 mmol/l the OGTT was performed. Of  
224,251 subjects, 21,851 (9.7%) had a 2-h finger blood glucose level ≥6.67 mmol/l after breakfast 
and 15,918 of them (73%) participated in the OGTT. 
4.2 The Beijing Project
4.2.1 Baseline survey 
The Beijing Project, as part of the National Diabetes Survey, was carried out between July 1994 and 
January 1995. 76 units in the Beijing area including 33 villages, 15 factories, 11 military camps, 
and 17 urban communities were randomly ascertained with a multi-stage sampling method. In these 
units, 20,682 inhabitants aged 25 – 82 years (64% of them aged 25 - 44 years) participated in the 
finger blood glucose screening survey. The participation rate was 92%. A total of 2,499 participants 
aged 25 – 80 years who at the screening had a 2-hour capillary blood glucose of ≥6.67 mmol/l were 
invited to participate in the OGTT. Among them, the OGTT was performed in 1,566 subjects 
(62.7%). Of these 1,566 subjects, after excluding 106 with known diabetes and 221 currently taking 
antihypertensive or hypolipidemic drugs, 305 with newly diagnosed diabetes and 934 without 
diabetes were included in the baseline study (article III). 
4.2.2 Follow-up survey 
From October 1999 to January 2000, the 5-year follow-up survey was carried out in subjects who 
participated in the OGTT at baseline. Of the initial 1,566 subjects, 483 had moved out of Beijing 
and 181 persons could not be followed up because of logistical reasons. The remaining 902 persons 
(57.6%) participated in the follow-up examination. The non-participants did not differ significantly 
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from participants in age, sex, BMI, WHR, FPG, 2-h PG, serum fasting and 2-hour postload insulin, 
TG, total cholesterol, timed 2-hour UAER, and the frequency of diabetes, hypertension, and obesity 
at baseline. Of the 902 subjects who participated in the follow-up study, 275 had diabetes at 
baseline, 68 currently took antihypertensive or hypolipidemic drugs and 129 developed type 2 
diabetes (61 men, 68 women) during the 5-year follow-up. Thus, 559 subjects without diabetes at 
baseline and without antihypertensive or hypolipidemic treatment were included in the study 
(article III); 627 subjects without diabetes at baseline were included in the study (article I, II, IV). 
The enrolment and examinations of subjects were conducted in accordance with the Helsinki 
Declaration. 
4.3 Measurements
The anthropometric and laboratory measurements were carried out at baseline and follow-up 
separately. The assay conditions, such as storage of the blood samples, experimental methods, kit 
producers, technicians, laboratory and instruments, in the two surveys were identical. The 
specifically trained physicians performed face-to-face interviews using a standardized 
questionnaire, which included questions about past medical history, family histories of diabetes, 
history of pharmacological treatment, smoking habits, occupation, and education. Family histories 
of diabetes, and antihypertensive and hypolipidaemic medication were dichotomized. Smoking 
status included current smokers and non-smokers. Occupation was classified as white collar or blue 
collar work. Three education categories were created according to the total number of years in 
school: 0–6, 7–12, and ≥13 years. 
Body weight of the subjects wearing light clothing without shoes was measured with 0.1 kg 
precision. Height was measured to the nearest 0.5 cm. BMI was calculated as the weight in 
kilograms divided by the square of the height in meters. WC was defined as the average of two 
measurements taken after inspiration and expiration at the midpoint between the lowest rib and iliac 
crest. Hip circumference was measured at the point of trochanter major. WHR was defined as WC 
to hip circumference. After each subject had been seated for five minutes, BP was measured twice 
to the nearest two mmHg from the left arm of the participant using a standard sphygmomanometer. 
The average of the two measurements was used for all analyses. DBP was recorded at the fifth 
Korotkoff sound.  
After 10 to 12 hours of an overnight fast each subject voided and then the fasting blood sample was 
collected. A 75 g anhydrous glucose dissolved in 300 ml of water was given orally over the course 
of five minutes and a second blood sample was drawn two hours later for the glucose and insulin 
determination, respectively. A urine sample was collected immediately after the 2-hour blood 
collection to quantify timed 2-hour UAER. Blood samples were immediately centrifuged and 
processed further. Plasma glucose was detected in duplicate within 2 hours by a glucose oxidase 
method at the Laboratory Center of Beijing Tongren Hospital. The blood samples for other assays 
had been kept in –80° C freezer for 2-8 months until they were analyzed. Serum insulin was 
determined by a double-antibody radioimmunoassay. Urinary albumin concentration was measured 
by radioimmunoassay. Their intra- and interassay CVs were <6% and <8% for insulin, <5% and 
<7% for urinary albumin. Serum total cholesterol and TG levels were measured by enzymatic 
methods.
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4.4 Statistical analyses 
The analysis of variance (one-way ANOVA for linear trends, univariate ANOVA and repeated-
measures ANOVA) and paired t tests were used to assess the continuous variables, while Chi-
square, the Mantel-Haenszel method and McNemar test were performed in categorical variables. 
Individual associations between variables were assessed using Pearson’s correlation coefficients. 
Factor analysis was conducted to examine how the major components of MetS relate to each other 
in article III. Logistic regression models were used to determine risk factors or risk factor clusters 
for the development of diabetes or IGR. All statistical analyses were done using SPSS 11.5 
software.  
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5. RESULTS 
5.1 Assessment for the sensitivity of four definitions (Article I) and the new IDF 
definition 
The AACE definition of MetS had the highest sensitivity for incident diabetes compared with the 
other three definitions both in men and women, respectively (0.61 and 0.58). Using the updated 
AACE criteria (AACEN) for analyses in which IFG as a component is included, the highest 
sensitivity still remained in men and women (0.69 and 0.66) despite the highest false positive rate 
(men: 0.39; women: 0.36). The sensitivity of the WHO definition of MetS was a little lower than 
that of the AACE definition in men (0.53) and women (0.42). The NCEP definition with a WC of 
102 cm in men had the lowest sensitivity among all definitions. However, it had the lowest false 
positive rate as well (0.09). Similarly, the EGIR definition was most insensitive (both men and 
women: 0.28) despite the lowest false positive rates (men: 0.09; women: 0.13). In addition, the 
NCEP definition has almost the same sensitivity as that of the WHO definition in women (0.41 and 
0.42, respectively), but the former had a lower false positive rate than the latter (0.16 vs 0.29).  
According to the recommended standards of obesity for Asians (BMI ≥25; WC ≥90 cm for men and 
≥80 cm for women) (Steering Committee of the Western Pacific Region of the World Health 
Organization 2000), the analyses were repeated by using the modified NCEP definition with WC ≥90 
cm in men and ≥80 cm in women (NCEPA). The sensitivity of the NCEPA definition for new-onset 
diabetes was improved to 0.40 (false positive rate: 0.20) in men and 0.49 (false positive rate: 0.24) in 
women. Using the modified WHO definition with WHR >0.90 (women >0.85) or BMI ≥25 kg/m2
(WHOA), the sensitivity of the WHOA definition was also improved (men: 0.58; women: 0.49), 
although the false positive rate rose a little (men: 0.31; women: 0.32). The recently suggested IDF 
definition was significantly associated with a 1.9-fold increased risk of developing diabetes in men and 
a 2.4-fold increased risk in women after adjustment for age, education, occupation, smoking, family 
history of diabetes, and total cholesterol (model 2). Interestingly, the definition was insensitive for 
predicting incident diabetes in men while it had better sensitivity in women (0.31 vs. 0.61). However, 
men had a lower false positive rate than women (0.20 vs. 0.34) (Figure 5.1). If using a modified IDF 
definition, in which IGT was included and central obesity was as one of the parallel components rather 
than as a requirement in the definition, the sensitivity could be improved to 0.49 in men and to 0.70 in 
women. In addition, a BMI of ≥25 kg/m2 and a WHR of >0.90 (women: >0.85) were associated with a 
2.3- to 2.5-fold increased risk of incident diabetes in men and a 2.2- to 3.0-fold increased risk in women 
in the model 2. However, a WC of ≥90 cm (women: ≥80cm) did not predict incident diabetes in the 
model (Table 5.1). 
5.2 Effects of IFG and IGT on predicting diabetes in men and women combined 
(Article II) 
When men and women were combined for analyses, subjects with both IFG and IGT had a OR of 
9.40 (95% CI, 4.58-19.29) for incident diabetes, compared with those with both NFG and NGT 
after adjustment of age, sex, smoking, SBP, BMI, family history of diabetes, total cholesterol, 
triglycerides, antihypertensive medication, occupation, education, and UAER. When fasting insulin 
was added into the model, however, the OR decreased to 8.91 (95%CI, 4.32-18.38). Subjects with 
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Figure 5.1 Sensitivity and false positive rate of the NCEP, NCEPA, WHO, WHOA, AACE, AACEN, EGIR and IDF 
definitions of MetS for incident diabetes in men and women. NCEPA: the modified NCEP criteria based on Asian 
criteria of obesity (WC ≥90cm in men; ≥80 cm in women); WHOA: the modified WHO criteria based on Asian criteria 
of obesity (BMI ≥25); AACEN: updated AACE criteria in which FPG 6.1-6.9 mmol/l was also included.  
 Table 5.1 Relative risks of incident diabetes from the new IDF definition of MetS or some individual components during the five-year follow-up   
 RR (95% CI)* 
Men (n=308) Women (n=319) 
Model 1 Model 2 Model 1  Model 2  
The metabolic syndrome  
   IDF definition 1.83 (1.01-3.33) 1.86 (1.01-3.60) 2.83 (1.62-4.96) 2.42 (1.30-4.49) 
The individual components of the metabolic syndrome 
  Waist circumference ≥ 90 cm (women: ≥ 80 cm) 1.44 (0.84-2.49) 1.24 (0.69-2.26) 1.84 (0.94-3.59) 1.98 (0.94-4.18) 
  Waist–to-hip ratio > 0.90 (women: > 0.85) 2.55 (1.45-4.50) 2.51 (1.36-4.66) 3.01 (1.63-5.55) 2.95 (1.46-5.93) 
  BMI ? 25 kg/m2 2.17 (1.23-3.83) 2.26 (1.22-4.18) 2.36 (1.37-4.07) 2.14 (1.17-3.93) 
*Model 1: Adjusted for age; model 2: adjusted for age, education. occupation, smoking, diabetic family history, and total cholesterol. 37
Table 5.2 Adjusted odds ratios (95% CI) for incident diabetes in 627 subjects with normal and abnormal glucose levels during 5- year follow-up* 
   Odds Ratio (95% CI)    
 Subjects Cumulative Incidence 
NO. (%) 
Model 1 Model 2 Model 3 Model 4 Model 5 
 n=627        
 NFG and NGT 358 51(14.2) 1.00 1.00 1.00 1.00 1.00 
 IFG and NGT 112 28 (25.0) 1.99 (1.18-3.37) 1.93 (1.08-3.45) 2.03 (1.12-3.67) 2.01 (1.11-3.66) 2.00 (1.15-3.71) 
 IGT and NFG 95 31 (32.6) 2.78 (1.64-4.69) 2.75 (1.54-4.90) 2.83 (1.56-5.11) 2.68 (1.45-4.96) 2.64 (1.47-5.03) 
 IFG and IGT 62 36 (58.1) 8.39 (4.66-15.12) 8.30 (4.25-16.22) 8.74 (4.39-17.40) 9.40 (4.58-19.29) 8.91 (4.32-18.38) 
 n=627 
New IFG criteria 
       
 NFG and NGT 209 26(12.4) 1.00 1.00 1.00 1.00 1.00 
 IFG and NGT 261 53 (20.3) 1.77 (1.06-2.95) 1.71 (0.95-3.06) 1.88 (1.03-3.43) 1.86 (1.01-3.42) 1.80 (0.98-3.33) 
 IGT and NFG 48 13 (27.1) 2.54 (1.18-5.43) 2.59 (1.13-5.94) 2.98 (1.28-6.97) 2.92 (1.21-7.05) 2.90 (1.19-7.05) 
 IFG and IGT 109 54 (49.5) 6.72 (3.83-11.78) 6.8 (3.31-11.91) 6.67 (3.45-12.86) 6.54 (3.33-12.83) 6.34 (3.21-12.51) 
*Adjusted for sex.   
Model 1: adjusted for age.  
Model 2: adjusted for age, smoking, SBP, BMI, family history of diabetes, total cholesterol, and triglycerides. 
Model 3: education, occupation and antihypertensive medication were added to model 2. 
Model 4: UAER was added to model 3. 
Model 5: fasting insulin was added to model 4. 
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isolated IGT had a higher OR than those with isolated IFG (2.64 vs. 2.00) after adjustment for the 
confounding factors in model 5 (Table 5.2). Based on the updated FPG value between 5.6-6.9 mmol/l 
for IFG, the number of individuals with IFG alone or with both IGT and IFG combined, increased 
dramatically compared with a reduction in the number of individuals with isolated IGT and with 
normoglycaemia. However, subjects with isolated IGT had a higher OR for incident diabetes than 
those with isolated IFG (2.90 vs. 1.80).  Subjects with both IGT and IFG combined still had the 
highest OR (6.34) after adjustment for the confounding factors in the model 5 (Table 5.2).  
5.3 MetS defined by factor analysis and incident diabetes  (Article III) 
5.3.1 Partial correlations between variables at baseline 
Among non-diabetic subjects, BMI and WHR correlated with SBP, DBP, and fasting and 2-h 
insulin both in men and women, after adjustment for age. Fasting and 2-h insulin correlated with 
most other variables, especially in men. Serum cholesterol had low correlations with most other 
parameters. Both SBP and DBP correlated significantly with UAER in men, but not in women. 
While among diabetic subjects, UAER correlated with FPG and 2-h PG in men and women. Serum 
cholesterol and triglycerides correlated strongly with 2-h PG in both sexes. Significant correlations 
were found between insulin and glucose in diabetic men and women (Table 5.3.1).  
5.3.2 Factor patterns in participants with NGT and with IGR 
Subjects with NGT had similar factor patterns to those with IGR (Figure 5.3.2). Factor loadings 
after varimax rotation showed that the first factor correlated with BMI, WHR, and fasting insulin 
levels; the second factor with SBP and DBP, the third factor with FPG, 2-h PG and 2-h insulin; and 
the fourth factor with serum cholesterol and triglycerides. In men FPG also loaded on the first 
factor. These four factors were interpreted as obesity/insulin resistance, BP, glucose/2-h insulin, and 
lipid factor, respectively.  
5.4 Changes in features of MetS and incident IGR or diabetes  (Article IV) 
.
5.4.1 Baseline and follow-up characteristics 
Baseline characteristics  
The subjects who retained IGR and who progressed from IGR to diabetes were older than those 
who retained NGT during follow-up. The subjects with IGR at baseline had higher FPG values than 
those with NGT at baseline, while those who progressed from NGT to IGR or diabetes during 
follow-up had higher 2-h PG values than those who retained NGT. Mean values of 2-h PG, BMI, 
triglycerides and 2-h insulin, and prevalence of obesity and dyslipidaemia were significantly 
correlated with glycemic deterioration during follow-up. Mean fasting insulin values and 
prevalence of hypertension in subjects with NGT at baseline, and prevalence of insulin resistance in 
subjects with IGR at baseline were significantly correlated with further glycemic deterioration.  
Table 5.3.1 Partial correlations between variables at baseline in non-diabetic and diabetic subjects by sex 
Men/women
N  BMI  WHR SBP DBP Log UAE TC Log TG Log Fin Log 2-h insulin FPG 2-hPG 
Non-diabetic subjects (men = 449 Women = 485) 
BMI   0.33*** 0.14* 0.30***    0.30*** 0.21** 0.24***  
WHR 0.33***  0.21** 0.23***    0.35*** 0.27*** 0.19**  
SBP 0.24** 0.15**  0.51*** 0.16*    0.18**  0.21** 
DBP  0.20*** 0.20*** 0.70***  0.26***  0.17* 0.16* 0.16* 0.17* 0.17* 
Log UAER   0.18***    0.18* 0.15* 0.23**   
TC    0.13*   0.24***  0.20**   
Log TG    0.15**  0.18**  0.17* 0.20** 0.13*  
Log Fin 0.26*** 0.23*** 0.29*** 0.18**     0.30*** 0.18**  
Log 2-h insulin 0.18** 0.18*** 0.12* 0.21***    0.26***  0.18** 0.47*** 
FPG   0.13* 0.15**     0.13*  0.24*** 
2-h PG 0.16**  0.22*** 0.22***     0.35*** 0.12*  
Diabetic subjects (men = 132 Women = 173) 
BMI   0.22*** 0.19**     0.30***    
WHR 0.24***      0.12* 0.12*    
SBP 0.22***   0.56*** 0.30***   0.12*    
DBP 0.12*  0.58***  0.17** 0.13*      
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Log UAER   0.27*** 0.17**   0.15** 0.18**  0.13* 0.26*** 
TC    0.13*   0.13*  0.13*  0.21*** 
Log TG  0.12*   0.11* 0.14**     0.16** 
Log Fin 0.30*** 0.16**   0.16**    0.31***   
Log 2-h insulin        0.28**    
FPG     0.14**      0.21*** 
2-h PG     0.22*** 0.20** 0.11*   0.35***  
Correlations for men are shown in the upper right corner of the matrix and for women in the lower left corner. The values of P>0.05 are omitted. 
*P<0.05, **P<0.01, ***P<0.001. All variables are adjusted for age. 
BMI, body mass index; WHR, waist-to- hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; UAER, urinary 
albumin excretion rate; TC, total cholesterol; TG, triglycerides; Fin, fasting insulin; FPG, fasting plasma glucose; 2-hPG, 2-h postload glucose.41
 Table 5.4.1 Baseline and follow-up characteristics by glucose status at baseline and during follow-up in 627 subjects 
At baseline  NGT   IGR    P value** 
At follow-up  NGT  IGR  DM  P trend* NGT  IGR  DM  P trend* 
n B 213 94 51  90 84 95   
F 213 94 51  90 84 95   
Age (yr) B 47 ± 11 48 ± 10 49 ± 11 NS 47 ± 11 51 ± 10 50 ± 10 NS 0.013 
F 52 ± 11 53 ± 10 54 ± 11 NS 52 ± 11 56 ± 10 55 ± 10  NS 0.005 
Sex (M/F)  B 96/117 53/41 22/29 NS 44/46 45/39 48/47 NS NS 
FPG (mmol/l) B 5.2 ± 0.6 5.4 ± 0.5 5.4 ± 0.6 NS    6.0 ± 0.7 6.0 ± 0.7 6.2 ± 0.7  NS <0.001 
F 5.0 ± 0.7  6.0 ± 0.7  7.3 ± 1.9   <0.001 5.0 ± 0.7  6.0 ± 0.6  7.9 ± 2.0  <0.001 <0.001 
2-h PG (mmol/l) B 5.6 ± 1.1  6.0 ± 1.2 6.2 ± 1.2 <0.001  7.2 ± 1.8  7.4 ± 1.8  8.4 ± 1.6 0.002 <0.001 
F 5.6 ± 1.1  7.9 ± 1.6  12.3 ± 4.1 <0.001 5.8 ± 1.2  8.6 ± 1.6  12.8 ± 3.1 <0.001 <0.001 
BMI (kg/m2) B 23.7 ± 3.2  24.9 ± 3.2  25.2 ± 3.7  <0.001  24.6 ± 3.3 24.9 ± 3.0  26.2 ± 3.5 0.002 <0.001 
F 24.6 ± 3.4  26.2 ± 5.2 26.1 ± 3.5 0.002 25.0 ± 3.5 26.1± 3.1  26.6 ± 3.2  0.001 <0.001 
SBP (mmHg) B 123 ± 22  126 ± 23 128 ± 23 NS 129 ± 23 129 ± 21 134 ± 22 NS 0.009 
F 124 ± 18  129 ± 17 129 ± 17  0.015 128 ± 17  129 ± 17  133 ± 18  NS 0.017 
DBP (mmHg) B 76 ± 12  79 ± 11  79 ± 12 NS    80 ± 13  80 ± 12  82 ± 11 NS 0.008 
F 79 ± 12  83 ± 10 82 ± 11   NS 81 ± 11  82 ± 12  85 ± 13   NS NS 
Cholesterol (mmol/l) B 4.7 ± 1.8  4.7 ± 1.7  4.8 ± 1.1  NS      4.7 ± 1.7  4.5 ± 1.6 5.1 ± 1.7 NS NS 
F 4.7 ± 1.1  4.8 ± 1.1 5.0 ± 1.0  NS 4.6 ± 1.0  5.2 ± 1.0 5.0 ± 1.0   0.003 0.002 
Triglycerides (mmol/l) B 1.3 ± 0.9 1.5 ± 1.1 1.7 ± 1.0 0.015         1.5 ± 0.9 1.7 ± 0.9 1.9 ± 1.0  0.001 <0.001 
F 1.3 ± 0.8  1.5 ±1.3  1.9 ± 1.3  <0.001 1.4 ± 0.8  1.8 ± 1.4 2.0 ± 1.1  <0.001 <0.001 
Fasting insulin  (pmol/l) † B 42 (39-44) 49 (44-53)  48 (42-55) 0.014 50 (46-56) 50 (45-56) 56 (51-62)  NS <0.001 
F 51 (46-57) 61 (52-72)  54 (41-57) 0.042 49 (41-57) 53 (44-62) 70 (59-82) 0.001 0.008 
2-h Insulin (pmol/l) † B 134 (122-147)  185 (159-211)  205 (169-249) <0.001  172 (150-198) 219 (189-254) 255 (222-294) <0.001 <0.001 
F 208 (186-234) 375 (315-447) 319 (251-405) <0.001 207 (174-247) 350 (291-420) 322 (270-383) <0.001 <0.001 
HOMA-B%†‡ B 64 (60-70)  73 (65-83) 69 (59-81)  NS             57 (51-65) 60 (53-69)  62 (55-69) NS 0.032 
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F 104 (91-119) 72 (60-89) 39 (30-51) <0.001 93 (76-114) 59 (48-72) 47 (39-57) <0.001 <0.001 
Obesity (%) B 31 45 47 0.002         46 48 64 0.02 <0.001 
F 36 65 61 0.03 46 67 70 0.002 <0.001 
Hypertention (%) B 26 40 55 0.001         47 41 51 NS <0.001 
F 34 56 67 0.012 57 57 68 0.041 <0.001 
Dyslipidemia (%)  B 24 28 45 0.03           37 41 57 0.003 <0.001 
F 24 31 45 0.02 27 44 61 <0.001 <0.001 
Insulin resistance (%) B 20 26 25 NS 24 30 41 0.028 0.012 
F 23 45 41 0.023 31 37 55 0.003 0.02 
Antihypertensive drugs (%) B 4 6 7 NS 5 7 7 NS NS 
F 4 7 7 NS 4 7 9 0.034 0.014 
Hypolipidemic drugs (%) B 3 4 4 NS 2 3 6 NS NS 
F 4 4 5 NS 3 3 5 NS NS 
Data are means ± SD or percentages. B, baseline; F, follow-up; obesity, BMI ?25.0 kg/m2; hypertension, SBP ?140 mm Hg and /or DBP ?90 mm Hg or using antihypertensive 
drugs; dyslipidemia, serum triglycerides ?1.7mmol/l or taking hypolipidemic medication; insulin resistance, upper fasting insulin quartile at baseline (B) or upper fasting insulin 
quartile at baseline cut-point (F). 
 †Geometric means (95% CI); *Linear trend in continuous variables or Chi-square (linear-by-linear association) in categorical variables; **Adjusted for age and sex among six 
groups. ‡HOMA-B% as an index of pancreatic β–cell function was calculated as 20 × fasting insulin in pmol/l/(fasting glucose in mmol/l – 3.5) 
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         Figure 5.3.2 Clusters of the risk variables of MS in men and women with NGT or IGR. BMI, body mass index; WHR, 
waist-to- hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; UAER, urinary albumin excretion rate; 
TC, total cholesterol; TG, triglycerides; Fins, fasting insulin; FPG, fasting plasma glucose; 2-h PG, 2-h postload 
glucose; 2-h Ins, 2-h postload insulin. 
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Subjects who retained NGT during the follow-up had a significantly lower prevalence of obesity, 
hypertension, and dyslipidaemia than those who worsened from NGT to IGR, those who progressed 
from NGT to diabetes, and those who had IGR at baseline. There was no difference in frequency of 
taking antihypertensive and/or hypolipidemic drugs between groups (Table 5.4.1).   
Follow-up characteristics  
No intervention program was carried out during the follow-up. By design, plasma glucose 
concentrations increased in the progressors. Mean values of BMI, triglycerides, fasting and 2-h 
insulin, and prevalence of obesity, hypertension, dyslipidaemia, and insulin resistance were 
significantly correlated with glycemic deterioration during the follow-up. Mean SBP in subjects 
with NGT at baseline, and mean total cholesterol values in subjects with IGR at baseline were 
significantly correlated with further glycemic deterioration during the follow-up. In contrast, mean 
values of HOMA-B% was negatively correlated with glycemic deterioration. More hypertensive 
subjects who progressed from IGR to diabetes took antihypertensive drugs during follow-up (Table 
5.4.1).
5.4.2 The association of changes in features of MetS with the risk of incident IGR or 
diabetes 
Change in obesity was significantly associated with a 2.1-fold increased risk of incident IGR or 
diabetes in an univariate model after adjustment for age, sex, family history of diabetes, smoking, 
education, occupation, antihypertensive and hypolipidemic medication, FPG, 2-h PG, SBP, BMI, 
total cholesterol, triglycerides, and fasting insulin at baseline. After further adjustment for change in 
hypertension, change in dyslipidaemia and change in insulin resistance, this association did not 
appreciably change. Change in hypertension, change in dyslipidaemia, or change in insulin 
resistance was not associated with the risk of incident IGR or diabetes (Table 5.4.2).  
Table 5.4.2 Adjusted odds ratios for incident IGR or diabetes in 627 nondiabetic subjects during 5- year follow-up*                               
 Univariate  Multivariate  
 OR   95%CI OR   95%CI 
Change in obesity (%) 2.11  1.31-3.42 2.20 1.36-3.57 
Change in hypertention (%) 1.51 0.87-2.63 1.69 0.95-3.00 
Change in dyslipidemia (%) 0.85 0.56-1.27 0.76 0.50-1.15 
Change in insulin resistance (%) 0.92 0.62-1.37 0.86 0.57-1.28 
*Adjusted for age, sex, family history of diabetes, smoking, education, occupation, antihypertensive and hypolipidemic 
medication, FPG, 2-h PG, SBP, BMI, total cholesterol, triglycerides and fasting insulin at baseline.
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6. DISCUSSION   
The aim of the present study was to evaluate the ability of the five definitions of MetS for 
prediction of type 2 diabetes and investigate how the components of MetS and changes in features 
of MetS related to the development of type 2 diabetes. The data collected in the National Diabetes 
Prevention Survey-Beijing Project during 1994-1995 and in the follow-up survey during 1999-2000 
offered the unique possibility to do the current study because all assessments of metabolic 
characteristics at baseline were repeated during the follow-up.  
6.1 Materials and methods  
China has the largest population in the world and is still a developing country. The prevalence of 
type 2 diabetes in China has been rising, but it is still lower compared with many Western 
countries. Therefore, it is of importance to find high-risk non-diabetic individuals in China and 
among them assess the major determinant factors for the development of type 2 diabetes. The 
present study introduced a capillary glucose pre-screening for OGTT at baseline for this purpose, 
while the initial participants at first survey were drawn randomly from a population. This selection 
procedure has two advantages: first, the yield of abnormal glucose tolerance at OGTT can be 
maximized in a large population survey; second, the follow-up study may be more efficient because 
more high-risk cases can be included at baseline only at cost of missing a small number of 
individuals with diabetes or IGT. Therefore, the study sample in this study represents a population-
based high-risk segment identified by raised post-prandial glucose rather than a general population. 
The limitation of the selection procedure may be that its findings cannot necessarily be applied to 
the general population. However, the major findings from the study are relevant for health 
promotion in the general population. 
Another limitation in this study is the lack of HDL-cholesterol values, although all other 
components of MetS in terms of different definitions were included. The lack of HDL-cholesterol 
would underestimate the prevalence of MetS and weaken the direct association between MetS and 
risk of type 2 diabetes to some extent. However, triglycerides ≥1.7 mmol/l or current use of 
hypolipidaemic drugs were defined as dyslipdaemia in the NCEP, the WHO, and the AACE 
definitions, which may minimize the missing cases of MetS determined by low HDL-cholesterol. 
Lack of information about physical activity, alcohol consumption, tea or coffee drinking, and 
dietary patterns is a third limitation. Besides, the relatively low follow-up rate is also a limitation in 
this study, although no difference in baseline characteristics was found between the participants and 
non-participants in the follow-up study.  
Regarding multifactorial diseases, it has been the epidemiologists’ convention to consider the 
independent weight of each risk factor in turn by multivariate analysis, thus adjusting for bias 
introduced by confounding variables. Such an approach, however, fails to take into account the 
manner in which related factors may confer the risk in concert and obscures attempts to gain 
understanding about the factors182,183. Factor analysis provided a method for addressing some of 
these challenges. It can reduce a large number of correlated variables to fewer uncorrelated factors. 
Therefore, the statistical technique for studies including interrelating variables was applied to 
investigate the risk factor clustering of MetS in this study. 
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6.2 Explanations for the lower sensitivity of some definitions of MetS for 
predicting diabetes  
6.2.1 Impact of cut-off points for obesity on the sensitivity 
Since almost all suggested cut-off points for abdominal obesity in the definitions of MetS were 
derived from the studies on a Caucasian population184, one of the most controversial aspects of 
MetS is without doubt the definition of obesity. This study showed that the WHO definition, 
including WHR >0.90 (women >0.85) or BMI ≥30 kg/m2, detected 53% of incident diabetes in 
Chinese men and 42% in women. However, a Finnish study found that the WHO definition 
identified 67% of incident diabetes in the Finnish men64. The NCEP definition, in which central 
obesity was defined as WC >102 cm was quite specific but insensitive in the Chinese men, 
detecting only 27% of incident diabetes. In contrast, 41% of incident diabetes was identified in the 
Finnish men. The lower sensitivity of the definitions for incident diabetes in the Chinese men may 
be attributable to the anthropometric indicators for classification of obesity. Among the Finnish 
men 8% (30%) of individuals without diabetes and 31% (59%) of incident diabetic individuals had 
a WC of >102 cm (94 cm), but only 3% (17%) of the Chinese men without diabetes and 8% (28%) 
of incident diabetic individuals had a WC of >102 cm (94 cm). Furthermore, only 9% of men and 
10% of women without diabetes in the Chinese population at baseline had a BMI of ≥30 kg/m2. In 
contrast, 20% of American white men and 21% white women, and 24% of American black men and 
44% of American black women without diabetes were obese (BMI ≥30 kg/m2)185. Because these 
assessments in the present study were based on the Chinese high-risk population, the difference in 
abdominal obesity between Chinese general populations and Caucasian populations would be 
expected to be much larger. When using the recommended standards of obesity for Asians, 63% of 
the Chinese men with incident diabetes and 44% of the men without diabetes were obese (BMI ≥25 
kg/m2), and 43% of the Chinese men with incident diabetes and 34% of the men without diabetes 
had a WC ≥90 cm. Clearly, these cut-offs were more suitable to detect incident diabetes for Chinese 
men. When applying the modified NCEP definition with a WC ≥ 90 cm in men and ≥80 cm in 
women, the sensitivity for incident diabetes was improved to 0.40 in men and to 0.49 in women in 
this study. Using the modified WHO definition with WHR >0.90 (women >0.85) or BMI ≥25 
kg/m2, the sensitivity was also improved (men: 0.58; women: 0.49). These findings thus confirm 
that the relation between adiposity and BMI varies by ethnicity186-188.  The NCEP definition with a 
waist cut-off of 102 cm or the EGIR definition with a waist cut-off of 94 cm did not seem very 
useful in Chinese men.  
6.2.2 Effect of combinations of different components to define MetS on the 
sensitivity 
Given the fact that insulin resistance appears central to the development of MetS, accurate 
quantification of insulin’s in vivo action, secretion, and disposal is necessary. While a combination 
of hyperglycemic and euglycemic-hyperinsulinemic clamp studies supplies the gold standard for 
quantifying these parameters, clamp studies are expensive and difficult tests to perform and require 
highly trained personnel. For the purpose of epidemiologic studies, several indices of insulin 
resistance such as ISI, fasting insulin, HOMA, QUICKI, etc., have been developed189-192. However, 
thus far there has been an apparent lack of consistency in the assessment of insulin resistance for 
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epidemiological studies. As there are different standards for assaying insulin, it is impossible to 
propose a universal cut-off. The EGIR recommended use of the upper quartile of fasting insulin 
concentrations, instead of clamp studies, to estimate insulin resistance. It also suggested that the 
upper quartile of fasting insulin concentrations was an essential requirement in the definition, while 
the WHO definition included either IGR or insulin resistance as an essential requirement. This 
study found that 55% of non-diabetic Chinese had IGR at baseline, and only 29% of non-diabetic 
and 34% of incident diabetic individuals had the highest quartile for fasting insulin concentrations. 
In contrast, 54% of Italians with incident diabetes were insulin resistant45. Clearly, the sensitivity of 
the EGIR definition was influenced by the essential requirement in the Chinese population. Since 
the insulin deficiency, rather than insulin resistance, plays a prominent role in the progression of 
diabetes in non-obese Chinese and Japanese populations compared to European populations193, the 
definition based on insulin resistance as a requirement of MetS may miss more incident cases of 
diabetes in Chinese. Recently, the new IDF definition defined ethnicity-specific central obesity 
(measured as WC) as a prerequisite for the diagnosis of MetS. IGT was excluded in the 
definition. However, there has not been a unified cut-off of obesity because of lack of consistent 
results from varied studies in China194,195. It has been controversial which anthropometric index of 
obesity is the best predictor of CHD or diabetes in Chinese196,197. The current study showed that 
IGT was a better predictor of type 2 diabetes than IFG in men, and a BMI of ≥25 kg/m2 or a WHR 
of >0.90 (women: >0.85) other than a WC of ≥90 cm (women: ≥80cm) was a better predictor of 
incident diabetes. Clearly, central obesity defined as WC ≥90 cm (women: ≥80cm) as a requirement 
and exclusion of IGT in the IDF definition mainly led to a lower sensitivity of the definition for 
predicting future diabetes in the Chinese population, especially in men. When using a modified IDF 
definition in which IGT was included and central obesity was as one of parallel components rather 
than as a requirement in the definition, this study showed that the sensitivity improved from a 
previous 0.31 to 0.49 in men. 
6.3 MetS defined by factor analysis and incident diabetes 
6.3.1 Pathophysiological mechanism of MetS   
An important feature of MetS is insulin resistance, characterized by increased fasting insulin levels 
among non-diabetic individuals2,190. However, whether insulin resistance really is the unifying 
underlying abnormality is still debatable198,199. Factor analysis has been used for decades to 
understand relations among psychometric variables, but only since 1994 has this method been used 
to understand relations among metabolic risk variables200. Factor analysis can reveal underlying 
patterns or structure among variables showing high degrees of intercorrelation. Since insulin 
resistance has been proposed as the underlying pathophysiological mechanism of MetS, if factor 
analysis reveals only one underlying factor, it may be interpreted as supporting the unity hypothesis 
that one unifying physiology (perhaps insulin resistance) underlies and accounts for the metabolic 
risk variable clustering201. However, this study did not just identify a single factor in non-diabetic 
individuals but a total of four factors that result in the clustering of the basic risk variables: 
obesity/insulin resistance, blood pressure, glucose/2-h insulin, and lipid factors. Similar results were 
observed in a study in non-diabetic elderly Japanese-Americans, in which four similar factors to this 
study were also found202. The studies in Korean men, non-Hispanic white, African-American, and 
Pima Indian populations identified two to four factors as well. In these studies the blood pressure 
factor was probably the most tenuously linked with other factors182,203,204. The results suggest that 
insulin resistance alone does not underlie all features of MetS, and more than one 
pathophysiological mechanism are present for the full expression of MetS. 
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6.3.2 Predictive factors of MetS defined by factor analysis for incident diabetes 
Factor analysis, a statistical technique for studies including interrelating variables, has been applied 
to investigate the risk factor clustering in MetS and to predict coronary heart disease or total and 
CVD mortality205,206. Thus far there have been only two studies relating the clustering of risk 
factors for MetS to incident diabetes using factor analysis. Neither of these two studies, however, 
analyzed the data separately by sex, nor included UAER into the variables among diabetic patients. 
A Finnish study population consisted of 309 siblings of diabetic (DM+) or non-diabetic (DM-)
probands63, which showed that factor analyses revealed four significant factors in both the DM+ and 
DM- groups. Of these, factor 1 was characterized by high loadings for BMI, hypertension, glucose 
area, insulin area (the highest loading), and triglycerides in both the DM+ and DM- groups. 
Therefore, factor 1 can be interpreted as a hyperinsulinemia factor. The hyperinsulinemia factor was 
similarly associated with the risk of developing diabetes in the two groups. Another study in Pima 
Indians also identified four factors including insulinemia, body size, blood pressure, and lipid 
metabolism65. The insulinemia factor was strongly associated with diabetes incidence. The body 
size and lipids factors also significantly predicted diabetes, whereas the blood pressure factor did 
not. The present study included UAER in the analyses and analyzed data for men and women 
separately. The results displayed that the glucose/2-h insulin factor and the obesity/insulin 
resistance factor were strong risk factors for type 2 diabetes, whereas the blood pressure factor and 
the lipid factor were not associated with the development of diabetes. This implied that different 
physiological processes associated with various components of MetS contained unique information 
about the diabetes risk in the Chinese population.  
6.3.3 Relationship between MetS and microalbuminuria 
A Korean study in a general population found that not only diabetes and hypertension, but also 
fasting hyperinsulinemia and WHR were independent factors associated with the presence of 
microalbuminuria. When the normotensive, non-diabetic subjects were analyzed separately, fasting 
hyperinsulinemia and IGT remained independent variables associated with the presence of 
microalbuminuria. These results showed that microalbuminuria in the Korean general population 
was associated with hyperinsulinemia and central obesity, and suggested that microalbuminuria was 
a feature of MetS independent of hypertension or type 2 diabetes207. Nevertheless, the Hoorn study 
in a Dutch population showed that microalbuminuria was independently associated with 
hypertension, diabetes, and WHR, with ORs of 3.33, 2.26, and 2.49, respectively. No associations 
were found between IGT, hyperinsulinaemia, insulin resistance or dyslipidaemia and 
microalbuminuria. Multiple logistic regression analyses in diabetic and non-diabetic subjects 
separately showed that microalbuminuria was independently associated only with hypertension 
(ORs 4.31 and 2.69)62. Using factor analysis, the IRAS displayed that the log albumin/creatinine 
ratio did not significantly load on the BP factor (loading: 0.30) in non-diabetic men204. No study 
thus far has included UAER into the variables among diabetic subjects using factor analysis. The 
current study showed that although the factor patterns were consistent in the analyses among men 
and women separately, there was a remarkable contrast in the patterns between subjects with and 
without diabetes. Among non-diabetic subjects UAER correlated significantly with both SBP and 
DBP only in men, but did not load on any factors. In contrast, among diabetic subjects UAER 
significantly loaded on the glucose factor, but UAER did not positively load on the blood pressure 
factor (loading: 0.39 in men; 0.37 in women). The results provide evidence that microalbuminuria 
is most likely to be a complication of hyperglycemia or hypertension rather than a marker of MetS. 
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6.4 The cumulative 5-year incidence of type 2 diabetes in China 
Although type 2 diabetes has a genetic predisposition, there is strong evidence that environmental 
factors such as obesity and physical inactivity play an important role in diabetic etiology. As the 
economy has quickly grown, traditional lifestyles have changed in China during the past 20 years. 
Diets are shifting towards higher fat and lower carbohydrate contents. The number of people who 
are overweight and had low physical activity is increasing rapidly around the country, especially in 
large cities. From 1989 to 1997 the prevalence of overweight (BMI ?25) in Chinese men tripled and 
among women it doubled208. The new data from the 4th CNHS showed that the prevalence of 
obesity (BMI ?30) and overweight (BMI ?25) in Chinese adults between 1992 and 2002 has 
increased by 97% and doubled, respectively. The prevalence of obesity in large cities in China is 
higher (12.3%) than the overall level of the country (7.1%). In 1994 the prevalence of type 2 
diabetes in Beijing was 3.4%, which was four times the overall prevalence of diabetes observed in 
1980. In the present study, 45.2% of participants were overweight (BMI≥25) at baseline, five years 
later the rate of overweight significantly increased to 52.8% adjusted for sexes and ages. The 
cumulative 5-year incidence of diabetes was 58.1% for participants with both IFG and IGT 
combined, 25.0% for participants with IFG alone, and 32.6% for those with isolated IGT at baseline 
in men and women combined analyses. The results were similar to the previous results from the 
Dutch population and in the Hong Kong Chinese42,43. However, the Chinese with NFG and NGT 
had a higher cumulative incidence of diabetes (14.2%) than the Dutch population (4.5%) and the 
Hong Kong Chinese (4.9%). Given the fact that the sample in the present study represents a 
population-based high-risk segment other than a general population, the selection procedure in this 
study may be a cause of the high cumulative incidence in those with NGT and NFG. Besides, the 
transition from a traditional lifestyle to a western one that occurred in China may be another cause. 
6.5 Impaired glucose tolerance as a predictor of diabetes in men and women
Although many prospective studies has showed that subjects with IGT have markedly higher risk 
for the development of type 2 diabetes and for all-cause and cardiovascular mortality than subjects 
with normal glucose41,209,210, less has been known about the effect of isolated IFG on the 
development of diabetes by gender. A Finnish study reported that the multivariate adjusted Cox 
hazard ratio was higher for isolated IGT (3.9, 95% CI 2.4-6.2) than for isolated IFG (2.3, 0.9-5.7) as 
compared with subjects with neither IFG nor IGT44. However, the subjects in the study were not 
stratified by sex. In the current study the analyses were carried out separately for men and women. 
Although both IGT and IFG combined were strongly associated with future diabetes in both men 
and women, isolated IGT appeared to be a stronger predictor for development of diabetes than 
isolated IFG in men. In contrast, there was no significant difference in ORs for future diabetes 
between isolated IFG and isolated IGT in women. Recently, the ADA has suggested that the cut-off 
point for IFG should be lowered from 6.1 mmol/l to 5.6 mmol/l, and that IFG should be redefined 
as an FPG of 5.6-6.9 mmol/l. Based on the updated cut-off point for IFG, both men and women 
with both IFG and IGT combined in this study still had the highest OR for the development of 
diabetes and also isolated IGT was a better predictor of incident diabetes than isolated IFG in 
Chinese men. Lowering the FPG cut-off point will however double the number of people with 
isolated IFG without improving the prediction. Thus, lowering the cut-off point of FPG does not 
resolve the problem that the use of FPG alone leads to false negative cases. Since there was a low 
participant rate (57.6%) at the follow-up, it was not certain if the finding that IGT was a stronger 
predictor than IFG in men was due to the bias. However, there were no differences in the baseline 
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characteristics between nonparticipants and participants. Furthermore, when the logistic regression 
analyses were performed in both men and women combined after adjustment for sex and the other 
confounding factors, the highest OR for future diabetes was still observed in those with both IFG 
and IGT combined, whereas those with isolated IGT had a slightly higher OR than those with 
isolated IFG (2.64 vs 2.00). This proportion of isolated IGT to isolated IFG in OR was similar to 
previous findings from the Hoorn Study (10.9 vs 10.0) where the analyses were not stratified for 
gender42. A prospective study on an Italian population, where 76.7% of total subjects were men also 
found that the OR for diabetes in the subjects with isolated IGT was higher than in those with 
isolated IFG (6.2 vs1.2)211. Whether IGT is a stronger predictor than IFG in men and what 
mechanism is involved for this sex-difference may need further study. 
6.6 The role of obesity in the development of IGR or diabetes  
There is consensus that individualized lifestyle modification is appropriate for all patients who are 
considered at risk for having MetS. Both adiposity and the level of physical activity are powerful 
modulators of insulin-mediated glucose disposal. More importantly, in contrast to the other factors 
that affect insulin action, they are modifiable by safe, straightforward lifestyle changes. Thus weight 
loss of 5-10% of body weight in overweight/obese individuals, who are also insulin resistant, will 
significantly enhance insulin sensitivity, lower ambient plasma insulin concentrations, and improve 
the manifestations of MetS212. The Da Qing IGT and Diabetes Study, the DPP and the DPS have 
confirmed that changes in lifestyle aimed at weight loss reduced the incidence of diabetes. The Da 
Qing IGT and Diabetes Study in China is the first lifestyle-intervention trial for preventing diabetes in 
the world. It randomized 577 subjects with IGT by clinic into the clinical trial, either to a control 
group or to one of three active treatment groups: diet only, exercise only, or diet plus exercise. 
Follow-up evaluation examinations were conducted at 2-year intervals over a 6-year period to identify 
subjects who developed type 2 diabetes. In a proportional hazards analysis adjusted for differences in 
baseline BMI and fasting glucose, the diet, exercise, and diet-plus-exercise interventions were 
associated with 31% (P < 0.03), 46% (P < 0.0005), and 42% (P < 0.005) reductions in risk of 
developing diabetes, respectively. Compared with the control group which had a reduction of 0.27 kg 
for weight, the diet, exercise, and diet-plus-exercise groups had a reduction of 0.93, 0.71 and 1.77 kg 
for weight, respectively. Furthermore, one of the goals for the lifestyle intervention was to achieve 
and maintain a BMI of 23 kg/m2 in the participants with BMI ? 25 kg/m2. In the present study, the 
subjects who remained NGT and those who progressed from NGT to diabetes during the follow-up 
had almost a similar increase in mean BMI. Nevertheless, the former still maintained a mean BMI 
below 25 kg/m2 during the follow-up, while the latter had a mean BMI of over 25 kg/m2.
Interestingly, BMI also increased in the subjects who reverted from IGR to NGT during follow-up, 
but their mean BMI maintained about 25 kg/m2 and no change in the prevalence of obesity was 
observed. Furthermore, an increase in obesity, rather than change in other features of MetS, predicted 
the progression of IGR or diabetes after adjustment of the confounding factors. These results 
implicate that obesity may be a more important risk factor for development of IGR or diabetes than 
other features of MetS. The lifestyle intervention aimed at preventing diabetes should place higher 
importance on obesity than IGR, because even IGR could still revert to a normal glucose state as long 
as an increase in obesity did not occur or mean BMI was kept below 25 kg/m2.
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7. SUMMARY AND CONCLUSSIONS 
This prospective study in China has provided an excellent opportunity to evaluate the sensitivity of 
different definitions of MetS for predicting diabetes, and to examine the relationship between MetS and 
incident diabetes. 
The NCEP, WHO, EGIR, AACE and IDF definitions of MetS appeared valid, detecting those at a 1.6- 
to 4.5-fold increased risk of developing diabetes during the follow-up in the Chinese high-risk 
population. The NCEP definition, in which the cut-off point of central obesity is based on the results 
obtained in a Caucasian population, did not seem to be sensitive in predicting diabetes in Chinese men. 
The EGIR definition, which includes insulin resistance as an essential requirement of MetS, missed 
more incident cases of diabetes in the Chinese. The IDF definition, in which IGT (actually, only fasting 
glucose is mentioned in the IDF definition) is excluded and central obesity is used as an essential 
requirement of MetS is insensitive for predicting diabetes in Chinese men.   
Both IFG and IGT combined were associated with an 8.8- to 9.4-fold increased risk of development of 
diabetes in Chinese men and women. Chinese men with isolated IGT had a 7.8-fold increased risk of 
incident diabetes.  
Factor analysis revealed consistent clusters of variables that were different in non-diabetic and diabetic 
subjects in the Chinese population.  UAER was associated with the glucose factor in diabetic subjects. 
Blood pressure was not linked to insulin resistance. The obesity/insulin resistance factor and the 
glucose/2-h insulin factor predicted the development of type 2 diabetes.  
Although the individuals who remained NGT and those who progressed from NGT to diabetes during 
the follow-up had an almost similar increase in mean BMI, the former still maintained a mean BMI of 
below 25 kg/m2 during the follow-up, while the latter had a mean BMI of over 25 kg/m2. Subjects who 
reverted from IGR to NGT had no change in the prevalence of obesity during the follow-up. An 
increase in obesity, rather than a change in other features of MetS, predicted the progression of IGR or 
diabetes after adjustment for the confounding factors. 
A single worldwide definition of MetS is convenient and useful in clinical practice and epidemiological 
studies. Since five definitions, especially the new IDF definition, have been released, the most important 
is to test their ability for predicting incident diabetes and CVD across ethnic groups. More information 
from different populations is needed for the further refinement of the definition of MetS. In addition, 
since MetS is not only associated with the elevated risk of diabetes but also with that of CVD, there is 
an urgent need to develop strategies to prevent the emerging global epidemic of MetS.  
In conclusion, further studies on the definition of MetS should focus on the potential ethnic differences 
in obesity and insulin resistance. Both IFG and IGT combined exhibit the strongest predictor for 
development of diabetes in both men and women compared with other categories of glucose 
homeostasis. Isolated IGT is a better predictor of incident diabetes than isolated IFG in Chinese men. 
Insulin resistance is not the only single unifying factor for the clustering of components of MetS. 
Different physiological processes associated with various components of MetS contain unique 
information about diabetes risks. Microalbuminuria is more likely to be a complication of the type 2 
diabetes or hypertension than a marker of MetS. Obesity may be a more important risk factor for the 
development of IGR or diabetes than other features of MetS. The lifestyle intervention aimed at 
preventing diabetes should place higher importance on obesity than IGR.  
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